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Abstract
Oral oncolytics continue to come to market at an unprecedented pace. Traditionally,
chemotherapy was delivered in the controlled environment of the infusion suite; however,
with the increasing use of oral oncolytics, the burden of administration and monitoring
has shifted to the patients and/or their caregiver. This paradigm shift, from intravenous
chemotherapy to oral chemotherapy, has created new challenges in cancer care. Despite
the seriousness of their diagnosis, oncology patients are not always adherent to these
requirements. Oncology nurses have always taken the lead in patient education, yet that
lead has mostly been in the context of intravenous chemotherapy. There is currently a
lack of evidence to guide oncology nurses with their interactions with patients on oral
chemotherapy. If patients are not adherent with their prescribed therapy, then progressive
disease and premature death may be the outcome of their non-adherence. This project
was a systematic review and synthesis of 51 articles on oral adherence and the subsequent
development of a guideline based on the evidence that nurses can use to guide their
interactions with patients on oral chemotherapy. The synthesis was divided into ways to
measure adherence, factors contributing to non-adherence, and interventions to improve
adherence. Knowing the factors contributing to non-adherence, how best to measure
adherence, and the interventions to improve adherence can assist the nurse to plan
individualized patient care. Adherence is critical for optimal patient outcomes and nurses
play a key role in helping patients remain adherent. Education, monitoring, and ongoing
support are necessary to help patients remain adherent and achieve optimal clinical
outcomes. The scholarly product, a guideline on oral adherence, can be used by nurses to
guide their interactions with adult patients on oral chemotherapy.
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Section 1: Nature of the Project
Introduction
Oral oncolytics continue to come to market at an unprecedented pace with the recent
approval of an increasing number of oral versus intravenous chemotherapy drugs. Michuad and
Choi (2008) reported that 25% of all oncolytics in research and development are oral. This influx
of oral agents into the oncology setting has brought to light a new and growing concern, that of
non-adherence in the oncology patient. Although non-adherence to medication regimens,
especially in the chronic disease setting, is not new, it has caught many in the oncology setting
off guard. Healthcare Practitioners presume that oncology patients would be adherent just due to
the severity of their disease, however this is not necessarily turning out to be the case. This shift
in treatment from the controlled environment of the infusion suite where patients are in an
environment monitored by nurses, to the patient’s home has created new challenges.
Patients and their caregivers are now responsible for adhering to complex dosing
regimens, monitoring symptoms, management of side effects and toxicities, coordination of drug
delivery, and dosing adjustments (as cited in Spoelstra et al., 2013, p. 19). Many oral oncolytics
have a narrow therapeutic window and adherence is important in preventing disease progression
and mortality. In a study by McCowan et al. (2008), the authors concluded that adherence to
tamoxifen that is less than 80% has a negative effect on survival. Exploring adherence, including
the ways in which it is measured, the factors contributing to non-adherence, and interventions
demonstrated to improve adherence can provide future direction to developing efforts that assist
patients to remain adherent and subsequently improve clinical outcomes. This project will
culminate in a guideline based on the evidence to assist nurses with their interactions with adult
patients on oral oncolytics.
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Problem Statement/Project Question
The clinical practice problem is the lack of evidence to guide nurse’s practice on
managing patients on oral oncolytics. The issue of non-adherence is multi-factorial and it appears
that many of the contributing factors that have been documented in the chronic disease setting
may be true for the oncology population. An important change in recent years related to cancer
treatment has been the increased understanding of signaling pathways that regulate cellular
activity thus allowing a cancer diagnosis to become a chronic disease for many.
Oral oncolytics provide patients with greater flexibility and convenience and less
disruption of activities of daily living (Schneider, Hess, & Gosselin, 2011). In a study by Liu,
Franssen, Fitch, and Warner (1997) of 103 patients, 89% reported a preference for oral
chemotherapy. In a quantitative review of 50 years of research, the adherence rate was 24.5% (as
cited in Spoelstra et al., 2013, p. 20). Reviews specific to oral oncolytics found adherence rates
between 16-100%. More specifically, adherence for patients with a 28 day cycle was 88%, for
patients with a 14 day on, 7 day off cycle was 36%, and 33% with a 7 day on, 7 day off cycle (as
cited in Given, Spoelstra, & Grant, 2011, p. 98). Nilsson et al. (2006) concluded from their study
that ambulatory patients who received anticancer drugs showed the same level of non-adherence
as patients treated with other types of drugs. According to Spoelstra and Given (2011), there are
few published studies that have focused on adherence to oral oncolytics. In a literature search by
the same authors to identify studies that examined adherence to oral antineoplastics among
cancer patients between 1975-2010, they found 30 adult studies (12 hormonal and 18 nonhormonal).
The problem that I addressed in this project was the increasing use of oral oncolytics and
the lack of evidence to guide nurses on how to best assist their patients to remain adherent. The
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focus of my project was to perform a systematic review and synthesis of the literature around
adherence to oral medications and develop a guideline for recommendations for practice.
Considering until recent years most chemotherapy was administered in the controlled
environment of the chemotherapy suite, oncology nurses have not had to deal with educating and
monitoring patients on oral adherence. For this reason, they are not well versed in what
interventions assist patients in being adherent. I focused my search into three separate areas or
themes: scales used to measure adherence, factors contributing to non-adherence, and
interventions to improve adherence. The subsequent synthesis of the literature around these areas
will allow for development of a guideline that nurses can use with their patients on oral
oncoloytics. The research questions were:
1) What interventions have been shown to improve adherence in patients prescribed oral
oncolytics,
2) What are the factors that contribute to lack of patient adherence to oral medications, and
3) How can adherence to oral therapy be assessed and evaluated?
Many interventions have been studied in the chronic disease setting such as by Ruddy,
Mayer, and Partridge (2009) looking at patient diaries, pill counts, serum or urine drug or
metabolite levels, and the medication event monitoring system (MEMS). Evidence retrieved in
this project was critiqued to determine the strength and quality of the evidence and if the
outcomes can be applied in the oncology setting. Understanding the reasons why patients do not
take their oral oncolytics as prescribed is important to development of potential interventions to
improve adherence. In this literature review, I also considered evidence regarding contributing
factors to non-adherence in order to synthesize this evidence as well.
Lastly, I included a review of instruments that are typically used to measure and monitor
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adherence. This provided the evidence on what measurement scales have been used successfully,
and that could be recommended for future use. Assessment and monitoring patient adherence is
key toward effective management of therapy. My review of measurement and assessment
methods enabled me to synthesize the evidence in this area.
Purpose Statement and Project Objectives
The purpose of this project was to synthesize the literature on adherence to oral drugs,
specifically oral oncolytics, in adult cancer patients in order to provide recommendations for
practice. The objectives for this project were first, to perform a systematic review of the
literature around adherence identifying causes, measurement tools, and interventions. My search
included both oncology and chronic disease literature dating from 1997-2013. Second, was a
critique of the literature. Third, was to create a synthesis of the evidence related to measuring
adherence, the contributing factors to non-adherence, and the interventions shown to improve
adherence and to develop a guideline for practice recommendations for nurses to use with their
patients on oral chemotherapy. This synthesis will be disseminated to the Oncology Nursing
Society (ONS) as they form a project team to determine if there is enough evidence to develop
an evidence-based resource on oral adherence for publication.
Significance to Practice
Oncology nurses have historically taken the lead in patient teaching for chemotherapy.
However, that chemotherapy was administered in the controlled environment of the office/clinic,
by the term coined in most practices as chemo nurses. When a patient receives a prescription for
an oral oncolytic, the patient often does not see a nurse. This is in large part due to the workflow
of the office. As this issue continues to come to light, clinics will need to rethink how they
manage patients on oral oncolytics. For those practices that have a system in place to teach these
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patients, that teaching is new in oncology since previous teaching revolved around intravenous
chemotherapy. Nurses are unfamiliar with what interventions have been shown to improve
adherence. Most of the literature is in the chronic disease setting as determined in my initial
literature search and was the foundation of the literature reviewed. Not much literature exists
regarding adherence in the oncology patient and it will likely be several more years before that
literature becomes more readily available. Side effects of oral oncolytics may be different from
oncolytics delivered via the intravenous route but they have the same potential for severity,
making patient education and monitoring equally important for both (Wood, 2012).
With the continued approval of oral oncolytics expected, patient education and
monitoring of patients on oral oncolytics will continue to increase in importance. Low treatment
adherence, even when patients are taking life-saving therapy, demonstrates the need for better
management and monitoring of patients on oral oncolytics. Poor adherence can severely impede
the efficacy of an oral oncolytic and if a prescriber is not aware that a patient is non-adherent,
disease progression may be attributed to lack of drug efficacy and may result in a regimen
change (Ruddy, Mayer, & Partridge, 2009). An understanding of both the barriers to adherence
and the strategies that can be used to effectively manage patients can equip oncology nurses with
the tools needed to improve adherence (Wood, 2012). This project produced a guideline on oral
adherence based on the evidence, which will assist nurses in their teaching of patients prescribed
oral oncolytics. If, in fact, nurses and clinical sites use the guideline and incorporate it into
clinical practice, it will have the potential to change the standard of care around how patients on
oral oncolytics are educated and monitored.
Possibly most important is that nurses have always taken the lead on patient education.
Barton (2011) posited that one of the most important aspects of helping patients adhere to oral
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treatment is to educate them about the role of therapy in their disease. Providing nurses the
evidence on factors contributing to non-adherence can assist nurses in doing this consistent with
the evidence. A better understanding of the reasons for non-adherence can help direct the
research to interventions to improve adherence. This project will contribute to the ONS’ Putting
Evidence into Practice (PEP) project team’s work. They will examine the evidence on a larger
scale and a final product will be published on the topic. It is too early to know exactly what that
final product will be as it is possible there may not be enough evidence to produce an evidencebased resource on oral adherence. If a PEP resource cannot be developed due to the lack of
evidence then it is anticipated a whitepaper or article around the state of the knowledge will be
published. However, whatever the final product is it will contribute to the body of knowledge for
oncology nurses caring for patients on oral oncolytics by providing them with what is currently
known, based on the evidence, on the topic.
Evidence-based Significance of the Project
It is well established that our nursing practice should be based on the evidence
(Newhouse, Dearholt, Poe, Pugh, & White, 2007). Nurses need to know what the best evidence
is around oral adherence. The significance of this project is the review and synthesis of the
literature around oral adherence where I provide a summary of the best, current evidence and
make it available to nurses. By understanding the state of knowledge around this topic it has
allowed me to identify areas for research, identify gaps in the research, and identify the best tools
related to measuring and assessment of adherence if they exist. Having a better understanding of
the current literature can also be used to design future interventions to improve adherence based
on what has already been researched. Nurses need to know what interventions work based on the
evidence so they can employ them in their practice of teaching patients about adherence.
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Social Change in Practice
Non-adherence has been associated with the increased consumption of healthcare
resources resulting in higher hospitalization rates and longer stays. It is estimated that nonadherence costs the United States healthcare system an estimated annual $100 billion to $300
billion while another estimate states that the hospital costs due to non-adherence amount to an
annual $8.5 billion price tag. Doggrell (2010) indicated that medication wastage costs the United
States over $1 billion per year. If a patient is non-adherent while participating in a clinical trial,
inaccurate conclusions and flawed dosing recommendations may result (Soper, Hubbard, &
Foster, 2009). Improving adherence can recognize a gain in health outcomes and a decrease in
wasted prescriptions filled but not used. Improved adherence confers economic benefits by
reducing the use of health services needed in disease exacerbation, crisis, or relapse. According
to Sabate and the World Health Organization (WHO) (2003), the indirect savings are recognized
in the preservation of quality of life and the social and vocational roles of patients (Sabate &
WHO, 2003). They also conclude strong evidence suggests that self-management programs in
patients with chronic diseases improves health status and reduces utilization and costs.
Additionally, when self-management and adherence programs are combined with regular
treatment and disease specific education significant improvements in health promoting
behaviors, cognitive symptom management, communication and disability management have
been recognized. The number of patients being hospitalized, days in the hospital, and the number
of outpatient visits has also been reduced (Sabate & WHO, 2003). Ultimately improving
adherence through patient education and monitoring should decrease the healthcare costs
associated with non-adherence and improve patient’s quality of life. According to Sabate and
WHO (2003), if we are able to increase the effectiveness of adherence interventions this may
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have a far greater impact on the health of the population than any improvement in specific
medical treatments.
From the patient’s perspective, a patient’s inability to adhere to their prescribed regimen
can negatively affect clinical benefit and result in treatment resistance, disease progression, and
death (Oncology Nursing Society [ONS], n.d.a.). Adhering to an oral cancer therapy can be a
challenging commitment for patients and their caregivers and oral cancer therapies are most
effective when patient adherence is optimized (ONS, n.d.b). The problem of non-adherence to
prescribed therapies is widespread and impacts all socioeconomic classes and disease states. In
the United States, 50-70% of patients do not take their medication as prescribed, 60% of patients
cannot actually identify their own meds, and 30-50% ignore, or otherwise compromise,
prescription related instructions (Soper, Hubbard, & Foster, 2009). In a study by Esposito,
Bagchi, Verdier, Bencio, and Kim (2009), where the authors examined medication adherence
and chronic heart failure, hospital and emergency department outcomes were lower for adherent
patients compared with non-adherent patients. Additionally, adherent patients were less likely to
have a hospitalization, had fewer hospitalizations per patient, were less likely to have an
emergency room visit, and had fewer emergency room visits per patient. Non-adherence
regardless if it is in the chronic disease setting or in the oncology setting has negative clinical
outcomes for patients and causes them to increase utilization of health care services.
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Definitions of Terms
Adherence to long-term therapy: “The extent to which a person’s behavior-taking medication,
following a diet, and/or executing lifestyle changes, corresponds with agreed upon
recommendations from a healthcare provider” (Sabate, & WHO, 2003, p. 17).
AGREE II Instrument: The Appraisal of Guidelines for Research and Evaluation (AGREE)
instrument evaluates the process of practice guideline development and the quality of reporting;
it is valid and reliable and comprises 23 items organized into six quality domains (Brouwers, M.,
Kho, M. E., Browman, G. P., Burgers, J. S. Cluzeau, F. Feder, G., … Zitzelsberger, L. 2010).
Cochrane Reviews: Systematic review of primary research in human health care and health
policy, and are internationally recognized as the highest standard in evidence-based health care
(The Cochrane Collaboration, 2012).
Intervention: The act of intervening, interfering, or interceding with the intent of modifying the
outcomes. In medicine, an intervention is usually undertaken to help treat or cure a condition
(Medicine Net, 2012).
Oncolytic: Pertaining to the destruction of tumor cells (The Free Dictionary, 2012a).
Oral Medication: The administration of a tablet, a capsule, an elixir, or a solution or other liquid
form of medication by mouth (The Free Dictionary, 2012b).
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Assumptions and Limitations
Oncology nurses typically take the lead in educating patients about intravenous
chemotherapy. Most office practices workflow is set up to allow this to take place. There is a
clear dichotomy in how patients are educated for intravenous chemotherapy versus oral
chemotherapy. Most of the education that takes place for patients receiving intravenous
chemotherapy is done by chemotherapy nurses, whereas, patients receiving a prescription for an
oral oncolytic generally never see a chemotherapy nurse simply due to the flow of the office.
Because this is a rising issue in oncology, there is limited data around adherence in the literature
specific to the oncology patient. Non-adherence is multifactorial and it appears that some of the
causes that contribute to non-adherence in the chronic disease setting are also causes in the
oncology setting.
The first limitation is the limited data around oral adherence in the oncology patient.
Most of the literature is in the chronic disease setting, which was reviewed for this project. The
second limitation is that there is plethora of literature around adherence in the chronic disease
setting and due to the time constraints of this project, all of the literature was not able to be
included in this review. The final limitation is that the synthesis of the evidence and
dissemination of it does not guarantee that nurses and/or clinical sites will use the information to
guide their nursing interactions with patients on oral oncolytics.
Summary
Nurses can have a significant influence on patient adherence by providing thorough and
timely patient and family education and by monitoring and managing side effects (Winkeljohn,
2010). Nurses can take the lead in developing programs, measurement tools, and interventions
that can improve adherence and patient outcomes. With this project it was my goal to synthesize
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the literature and provide evidence-based information in order to build a guideline on oral
adherence. It was also my goal to assist nurses with implementing this guideline. The upcoming
sections will examine the current literature on the topic of adherence, the conceptual framework
and evaluation method of the project and the synthesis of the literature examined to develop the
guideline on oral oncolytics.
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Section 2: Literature Review
Specific Literature
Adherence to long-term therapy is defined as “the extent to which a person’s behaviortaking medication, following a diet, and/or executing lifestyle changes corresponds with agreed
upon recommendations from a healthcare provider” (Sabate & WHO, 2003, p. 17). The literature
is sparse around adherence specific to the oncology population. This is likely in part because
there has been a significant span of time between the first few early oral oncolytics and the
recent approval of many oral oncolytics over the last several years.
According to Michaud and Choi (2008) with 25% of current oncolytics in research and
development being oral this issue will only increase in prevalence. The rates of non-adherence
vary in the literature but the first cancer observation studies were done with hormonal therapy in
breast cancer and reported adherence rates from 20%-100% (Regnier, Poirson, Nourissat,
Jacquin, Guastalla, & Chauvin, 2010). In the 1990’s researchers discovered signaling pathways
that regulate cellular activities, and found alterations in these pathways in cancer cells and this
science has lead to the development of targeted therapies, a large class of oral oncolytics
(Foulon, Schoffski, & Walter, 2011).
For decades, most chemotherapy was administered intravenously and services were
organized based on this type. The shift to treating cancer with oral agents has created a new
paradigm, challenging traditional attitudes toward cancer care and requiring new concepts of
organization in oncology care and services (Foulon et al., 2011). Oral therapy is often preferred
by patients over intravenous therapy for several reasons: (a) oral therapy can promote a feeling
of control; (b) decrease interference with work and social activities; (c) eliminate travel time to
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an infusion clinic; and (d) eliminate the discomfort and need for a peripheral intravenous line (as
cited in Wood, 2012, p. 432).
Additionally, patients are willing to accept oral therapy as long as side effects are not
worse than those expected with intravenous treatment and the greater sense of control over their
therapy is viewed as a benefit of oral versus intravenous (Foulon et al., 2011). For patients on
oral therapy, the burden of treatment administration is shifted to the patient, causing greater
difficulties in assessing treatment adherence and monitoring of side effects than with patients
receiving intravenous treatment (Wood, 2012). Given that efficacy is not compromised, most
patients prefer oral to intravenous. According to the National Comprehensive Cancer Network, a
key factor in assessing appropriateness for prescribing oral anti-cancer treatment is adherence (as
cited in Foulon, et al., 2011, p. 87).

General Literature
Causes of Non-Adherence
The literature search revealed the causes for non-adherence to be multi-factorial and
include lack of understanding proper treatment administration, complex dosing regimens,
interaction with other medications, timing of doses in relation to food intake, cost, and side
effects (Wood, 2012). Atkins and Fallowfield (2006) posited that adherence is not necessarily
related to socio-demographic factors such as age, sex, level of education, or race but that patients
are less likely to adhere to those therapies that have adverse side-effects, are complex, and/or last
longer. They go on to cite Elwyn and colleagues who suggest that intentional non-adherence is
the result of three factors: (a) a lack of information about the advantages and disadvantages of
the treatment; (b) when the benefits of the treatment are not obvious; and (c) the psychological
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adaptation required to see oneself in need of treatment. Adherence is less likely where the
benefits of the drug are not immediately obvious. This is significant for women with a diagnosis
of breast cancer on hormonal therapy for 5 years, which does not offer a guarantee of recurrencefree survival while producing side effects.
Another issue demonstrated in an international survey conducted by Kav et al., (2008) is
that 47% of nurses reported they felt inadequately educated on oral chemotherapy drugs (Kav et
al., 2008). Citing this study in his own research, Wood posited that patient education can
promote a better understanding of the patient treatment regimen and highlight the importance of
adherence (Wood 2012). However, Wood concludes that it appears that before nurses can
educate patients they themselves need education on the drugs. This presents another issue that is
outside the scope of this project. According to Hede (2009), there is no procedure, in any office,
to effectively prescribe and manage oral oncolytics.
Adherence to Cancer Agents
In a study performed by Atkins and Fallowfield (2006), the authors concluded that 55%
of woman currently receiving medication for their breast cancer did not adhere to the treatment
regimen. In addition, they found that 54% of women prescribed tamoxifen and 61% prescribed
an aromatase inhibitor reported non-adherence. In a study completed by Barron, Connolly,
Bennett et al., (cited by Schneider, Hess, and Gosselin (2011)), researchers found that within 1
year and within 3.5 years of starting tamoxifen, 22.1% and 35.2% of patients had discontinued
therapy. Partridge, Philip, Winer, and Avorn (2003) reported adherence rates dropped from 87%
in the first year to 50% by year four for breast cancer patients being treated with tamoxifen for
five years.

15
As demonstrated by these data, much of the research related to the oncology patient has
been in the hormonal agents as this was the largest group of oral agents used in cancer treatment
until the recent increase in targeted oral anti neoplastic agents. In a study specific to oral
oncolytics, Lebovits, Strain, Schleifer, Tanaka, Bhardway, and Masse (1990) reported a 43% rate
of non-adherence for breast cancer patients taking oral cyclophosphamide and/or prednisone.
Lastly, in a study by Levine et al. (1987), serum drug metabolites demonstrated that only 26.8%
of patients had adequate levels of prednisone and 16.8% had adequate levels of allopurinol while
the patient self-reports of adherence were greatly over-estimated. The adherence rates in the
aforementioned studies indicate that there is significant room for improving adherence to oral
cancer therapy.
Measuring Adherence
A current challenge in monitoring adherence is that no gold standard currently exists.
Little research has been done to measure adherence specific to the oncology patient and the
definition of adherence varies between studies. Studies have shown that adherence measures
have limitations, which then beckons the question of how best to measure drug-taking behavior
(Spoelstra & Given, 2011). Self-reporting has traditionally been used to measure adherence but
this method is fraught with inaccuracies as patients tend to over-report their drug taking (Wood,
2012). Additionally, medication possession ratio as a measurement scale is used frequently in
studies to examine adherence however, it is most commonly seen in the chronic disease
literature.
It is evident that more current research needs to be conducted now that there are many
new oral oncolytics on the market. Researchers and practitioners need to determine if the reasons
for non-adherence in the oncology setting are similar to those in the chronic disease setting and
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what interventions oncology patients find most helpful. Ruddy, Mayer, and Partridge (2011)
suggested that studies need to be done to investigate which diseases and which therapies are
significantly impaired by missed doses so that interventions to optimize adherence can be
targeted to the patients who are most in need.
There is a plethora of literature around adherence in the chronic disease setting. A
MEDLINE and CINAHL search that I conducted returned over 7,000 articles. People are living
longer and longer life is accompanied by an increase in chronic conditions (Williams, Manias, &
Walker, 2008). Prescribing medications and patient’s adherence is key to managing these chronic
conditions. The effectiveness of medications and their long-term benefits depend on patient
adherence to their prescribed regimen (Williams et al., 2008). In patients with diabetes, up to
37% have discontinued oral hypoglycemic drugs within one year of initiating treatment (Farmer
et al., 2012). In Human Immunodeficiency Virus (HIV) patients, where adherence rates need to
remain >90% to suppress the virus, adherence rates are reported to be 75-80% with rates
declining even further as the length of time on therapy increases (Fisher et al., 2011). DiMatteo
(2004) performed a quantitative review of 50 years of research and reported that medication
adherence is approximately 24.5%. According to Sabate and WHO (2003, p. 11), there is strong
evidence that many patients with chronic illness have difficulty adhering to their recommended
regimens and that 50% of patients who have chronic diseases do not take their medicines.
Poor adherence is the primary reason for sub-optimal clinical benefit and causes medical
and psychosocial complications of disease, reduces patient’s quality of life, and wastes
healthcare resources. These direct consequences impair the ability of the healthcare systems
around the world to achieve population health goals. The report goes on to say “the conclusions
of research in this area are unequivocal-adherence problems are observed in all situations where
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the self administration of treatment is required, regardless of type of disease, disease severity,
and accessibility to health resources” (p. 11).
According to Williams, Manias, and Walker (2008) 30-60% of people are non-adherent
to prescribed medications and this figure rises when multiple chronic conditions are involved.
Adherence can slow disease progression and reduce health care costs. In a systematic review in
people with multiple chronic illnesses, adherence was not routinely defined and was measured
using different self-report tools and estimates of adherence. In this same analysis, investigators in
prospective intervention studies recommend combinations of tailored educational, behavioral,
and affective strategies that include family support and regular patient contact. Williams et al.
conclude that healthcare systems that recognize, value, and fund initiatives, which support
consumers to take medications as prescribed are essential (Williams et al., 2008). Additionally,
they posit that nurses need to know how best to help and advocate for patients based on the
evidence.
Conceptual Model
Evidence-based practice is a problem-solving approach to clinical decision making that
integrates the best available scientific evidence with the best available experiential evidence
(Newhouse et al., 2007). Nurses using evidence-based practice as a foundation for their practice
are able to enlighten practice and add value to the patient experience. Nursing practice based on
the evidence is critical to realizing healthcare improvements and cost savings (Newhouse et al.,
2007). According to Newhouse et al., (2007), the key assumptions of evidence-based nursing
practice include: (a) nursing is both a science and applied profession, (b) knowledge is important
to professional practice and the limits to knowledge must be identified, (c) not all evidence is
created equal, and there is a need to use the best available evidence, and (d) evidence-based
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practice contributes to improved outcomes.
The evidence-based practice model that I used to guide my DNP project was the Johns
Hopkins Nursing Evidence-Based Practice Model (JHNEBP). I selected this model because of its
simplicity and ease of applying it to the research process and more specifically to my project.
The model can be described as PET: practice question, evidence, and translation. The first phase
is the development of an answerable, evidence-based question. The second phase is the search
for, and appraisal of, the best available evidence. The last phase, translation, is determining if the
changes to practice are feasible.
Developing questions allows researchers to determine what information to seek and the
direction in which to search and the question should be clear, accurate, precise, and relevant
(Newhouse et al., 2007). Practice settings provide the source of most evidence-based practice
questions. Practice issues for inquiry can come from a multitude of sources including safety/risk
management concerns, unsatisfactory patient outcomes, wide variations in practice, financial or
cost concerns, differences between hospital and community practice, clinical practice issues of
concern, procedures or processes that waste time, or practices with no scientific basis (Newhouse
et al., 2007). My practice question arose from a clinical practice issue of concern, that being lack
of patient education and monitoring of patients prescribed oral oncolytics and its contribution to
non-adherence.
The second phase requires proficiency in seeking information, analyzing, synthesizing,
interpreting, and drawing conclusions from available information. Rating scales are used to
provide a structured way to enhance the critical thinking skills of the reviewer by applying
standardized levels to evidence to differentiate among evidence of varying strengths and quality
(Newhouse et al., 2007). Once the literature has been reviewed and synthesized, then the
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determination needs to be if it is appropriate to move to the last step in the process, which is
translation. The first step in translation is asking: Should practitioners implement this practice
recommendation? The steps involved in translation involve assessing the feasibility and
appropriateness of the recommendation, creating an action plan, pilot on a small scale, evaluate
the change, report it to the appropriate stakeholders, foster support, wider implementation plan,
and communicate the findings (Newhouse et al., 2007).
The model includes a set of tools for use at each of the phases including an evidence
appraisal guideline, a review tool for scientific evidence, and a summary of evidence review and
recommendations (White & Dudley-Brown, 2012). Specifically, the JHNEBP Research
Evidence Appraisal form has areas addressing the strength of study design, results, and
conclusions. These components are included in the ONS’s form that I will use for documentation
of my article critiques since it is my hope that this work will continue on with ONS and
culminate in a formal evidence-based guideline published by them. Having my critiques on their
form will facilitate this ongoing process. I believe this model fits nicely with my systematic
review around adherence to oral oncolytics and developing an evidence-based resource for
oncology nurses on the topic. See Appendix A for the schematic of the conceptual model for this
project.
There are several variables that could be the result of this project. The first variable is the
literature may demonstrate that there is not enough evidence around interventions that have been
shown to improve adherence. It is possible that there is not enough literature around
interventions to improve adherence in the oncology setting but it is possible that the chronic
setting literature may not produce enough data to support interventions that improve adherence.
The second variable is there are proven interventions in the chronic disease setting but they are
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not applicable in the oncology setting. For example, decreasing pill burden improves adherence
but this may not be possible with oral oncolytics in the current marketplace but could prove to be
valuable insight for drug manufacturers. The final outcome variable is that at least some of the
interventions that have been shown to improve adherence in the chronic disease setting could be
applicable in the oncology setting with oral oncolytics, and I will present this information in my
synthesis of the literature. In the upcoming section, the project design, data collection, and
project evaluation will be discussed.
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Section 3: Methodology
Project Design
This project was a systematic review and synthesis of the literature. The purpose of a
systematic review is to synthesize the best available research on a specific question. In my
review, I used a transparent procedure to find, evaluate, and synthesize the results of the existing
research. A systematic review must have clear inclusion/exclusion criteria, an explicit search
strategy, systematic coding and analysis of included studies and a meta-analysis (The Campbell
Collaboration, n.d.).
Cochrane Reviews are systematic reviews of primary research in health care. These
reviews are internationally recognized as the highest standard in evidence-based healthcare. Each
systematic review addresses a clearly formulated question. All of the existing, primary research
that meets certain criteria is searched for, collated, and assessed using stringent guidelines to
establish whether or not there is conclusive evidence about a specific treatment (The Cochrane
Collection, 2012). Often, an individual or company might actively seek to discuss only the
research that supports their opinions or commercial interests. The Cochrane Review avoids this
by using predefined, rigorous, and explicit methodology.
The Cochrane Review is a scientific investigation in itself, with a preplanned methods
section and an assembly of original studies, which are comprised of mostly randomized clinical
trials and the results of these multiple primary investigations are synthesized by using strategies
that limit bias and random error. These strategies include a comprehensive search of all relevant
studies and the use of explicit, reproducible criteria in the studies selected for review. The
primary research designs and study characteristics are appraised, data synthesized, and results
interpreted (The Cochrane Collection, 2012).
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I selected the systematic review because it allows for review of the evidence around oral
adherence and more specifically oral oncolytics. It would help me to identify gaps in the
research, and the synthesis would provide nurses with the evidence of what interventions have
been shown to improve adherence. As previously stated, most oncology nurses have been
involved in the teaching, administration, and monitoring of intravenous chemotherapy in the
infusion suite. This is a new area of clinical concern in the oncology setting and, in performing
the systematic review I will provide nurses with the evidence to guide their practice.
The literature on oral adherence, specific to the oncology patient, is sparse but growing as
the topic has been in the limelight for the past several years. Most of the literature on adherence
to oral medications is in the chronic disease setting and because there may be valuable
information around causes, scales used to measure adherence, and successful interventions my
review included this literature as well. I expected that most of the literature that I reviewed
would be of a mixed method approach and that turned out to be true. It combined quantitative
data around adherence rates with qualitative data around understanding the causes of nonadherence and what interventions patients find useful. According to Terry (2012, p. 13), the
practitioner who conducts a systematic review is able to make an objective assessment of the
available evidence, specifically of the outcomes of particular interventions that could be
implemented and that evidence will be located, evaluated, and consolidated into a comprehensive
and unbiased summary. This is the foundation for this project.
I searched the literature using MEDLINE, PubMed, CINAHL, and PsycINFO.
Additionally, reference lists of papers that were eligible for inclusion in the systematic review
were scanned for additional citations. The literature search of the electronic databases combined
the following terms: medication adherence and oncology and/or cancer and/or neoplasm and/or
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oral and/or chronic disease. The search included the following designs: systematic reviews,
meta-analysis, randomized controlled trials, and non-randomized comparative cohort studies. I
selected articles for inclusion in the evidence series if the authors reported data on measuring
adherence, factors contributing to non-adherence, and interventions to improve adherence. Case
reports, letters, and editorials were not considered for inclusion. Additionally, articles that
included pediatrics, depression, cognitive disorders, psychiatric disorders, pregnancy, substance
abuse, or measured adherence in clinical trials were excluded.
Data Collection
This project was a systematic review of the literature around adherence, including in both
the oncology and chronic disease populations. I reviewed 119 articles that were the basis for the
review and synthesis. The articles that I included were on adherence to oral medications
specifically focusing on measurement scales, factors contributing to non-adherence and
interventions to improve adherence. My inclusion/exclusion criteria and Medical Subject
Headings (MeSH) terms were established. Inclusion criteria included: medication adherence,
medication compliance, causes/factors of non-adherence, measurement scales of adherence,
interventions for adherence, oral medication, peer reviewed, 1997-2013, adult, and English. The
exclusion criteria included: pediatrics, depression, cognitive disorders, psychiatric disorders,
pregnancy, and substance abuse. The MeSH terms were: medication adherence, medication
compliance, oncology and/or cancer and/or chronic disease and/or oral.
Data from the literature was collected via a standard form that the ONS currently uses for
their review of the literature. Since this project will be used in the consideration of ongoing
development of the topic by ONS, having the reviews on their form will more easily allow for
the work to continue if they deem appropriate. The form titled, ONS PEP Research Summary
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Form-July 2012 Version includes the following sections: (a) study reference information, (b)
study purpose, (c) intervention description, (d) sample characteristics, (e) setting, (f) phase of
care and clinical applications, (g) study design, (h) measurement/instruments, (i) results, (j)
conclusions, (k) limitations, and (l) nursing implications.
I sorted the data for contributing factors of non-adherence, measurement scales, and
interventions. Ultimately the data was reviewed, summarized, and synthesized. I then organized
the synthesized data in an excel spreadsheet for ease of reading and identifying trends. This also
followed the format ONS uses for its PEP resources. Additionally, each article that I included
was graded based on the JHNBEP model for strength and quality of the evidence.
An Institutional Review Board (IRB) is a committee whose primary responsibility is to
protect the rights and welfare of human research subjects as it reviews research proposals to
ensure risks have been minimized and the potential for benefit has been maximized for the
human subjects participating in the research. Participation in research is voluntary and requires
legally effective informed consent. The IRB is required by federal and state laws and applies
additional safeguards to vulnerable populations participating in research which includes children,
prisoners, pregnant women, fetuses, and physically, mentally, economically, or educationally
disadvantaged persons (The Ohio State University, 2013).
The IRB at Walden University is responsible for ensuring that Walden University
research complies with the university’s ethical standards as well as United States federal
regulations. IRB applications are required by all students and faculty members conducting
research projects involving collection or analysis of data (Walden University, n.d.). The IRB
approval for this project is 05-06-13-0327445.
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Evaluation Plan
I evaluated the final outcome of this project, a guideline on oral adherence, in a manner
similar to the evaluation of published guidelines. Additionally, in the case of this systematic
review and synthesis of the literature, evaluation should determine if it was done in a manner
consistent with evaluating this type of work. This project was evaluated by The Appraisal of
Guidelines for Research and Evaluation Instrument (AGREE). The AGREE Instrument was
published in 2003 by a group of international guideline developers and researchers called the
Agree Collaboration. The original AGREE Instrument was a 23-item tool comprising six quality
domains. It was developed to address the issue of variability in guideline quality and the tool
assesses the methodological rigour and transparency in which a guideline is developed. The
original AGREE Instrument has been refined and the purpose of the AGREE II Instrument is to
provide a framework to: (a) assess the quality of the guidelines, (b) provide a methodological
strategy for the development of guidelines, and (c) inform what information and how information
ought to be reported in guidelines. The AGREE II Instrument is also a 23-item tool organized
into six domains: (a) scope and purpose, (b) stakeholder involvement, (c) rigour of development,
(d) clarity of presentation, (e) applicability, and (f) editorial independence. The instrument is
generic and can be applied to guidelines in any disease area targeting any steps in the health care
continuum, including those for health promotion, public health, screening, diagnosis, treatment,
or interventions (Brouwers et al., 2010).
The AGREE II Instrument is more comprehensive than what is required for evaluation of
this project and was not used in its totality, especially given the fact that my final outcome will
not be a true guideline. Out of the aforementioned six domains, the sections that I utilized to
review my work were domain number three, rigour of development and domain number four,
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clarity of presentation.
The long-term effects of my evaluation plan included disseminating the information to
the ONS PEP project team on oral adherence and to my local ONS chapter. This project will
provide valuable information as we continue to evaluate what the most helpful information is to
educate oncology nurses on improving oral adherence based on the evidence. Additionally, I
planned to continue to participate in the oral adherence project team now that ONS has decided
to move forward with developing the topic. The short-term effects were to provide updates on
the literature review as I progressed through it to ONS. Evaluating the intermediate health
outcomes as a result of implementation of my project are outside the scope of it. It will be up to
the nurses and/or clinical sites to use the information and make practice changes according to the
evidence that my resource provides.
Summary
My approach with this DNP project was similar to the approach used in the Cochrane
Reviews. I performed a systematic review of the literature and synthesized it to develop a
guideline around adherence to oral therapies and more specifically oral oncolytics. When
completed, my project resulted in a guideline based on the evidence that guides nursing
interactions on adherence in the oncology patient prescribed oral oncolytics. If nurses can be
provided with interventions that have been shown to improve adherence they can and should
focus their teaching based on the evidence and those interventions that can improve adherence.
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Section 4: Discussion and Implications
Project Summary and Evaluation Report
The purpose of this project was to synthesize the literature on adherence to oral drugs,
specifically oral oncolytics, in adult cancer patients in order to provide recommendations for
practice. The end product of this systematic review and synthesis of the literature is a Guideline
on Oral Adherence, which I present in Section 5. The supporting evidence that I used to make
the recommendations and develop the guideline is included in Appendix B. The guideline
followed the format of the Cochrane Review, and includes a background, objective, search
strategy, selection criteria, data collection and analysis, main results, and author’s conclusion. I
evaluated the project using the AGREE II tool.
As I described in Section 3, this tool was intended to evaluate published guidelines to
address the issue of variability in guideline quality. It is a tool that assesses the methodological
rigor and transparency in which the guideline is addressed (Brouwers et al., 2010). The guideline
developed for this project is not a guideline in the truest sense of the word and therefore portions
of the AGREE II tool are not applicable for evaluating this guideline. For example, stakeholder
involvement, applicability which includes monitoring and/or auditing criteria, and editorial
independence do not apply to this project. Domains Three and Four will be used to evaluate the
guideline.
Domain Three of the AGREE tool evaluates the rigor of development. It determines if:
(a) systematic methods were used to search for the evidence, (b) the criteria for selecting the
evidence are clearly described, (c) the strengths and limitation of the body of evidence have been
considered in formulating the evidence, (d) the methods for formulating the recommendations
are clearly described, (e) the health benefits, side effects, and risks have been considered in

28
formulating the recommendations, (f) there is an explicit link between the recommendations and
the supporting evidence, (g) the guideline has been externally reviewed by experts prior to its
publication, and (h) a procedure for updating the guidelines is provided. This guideline met
criteria for items one to six and can be evidenced by viewing the guideline. Criteria seven and
eight are not applicable to this guideline.
Domain Four evaluates the guideline for clarity of presentation: (a) is the
recommendations are specific and unambiguous, (b) the different options for management of the
condition or health issue are clearly presented, and (c) key recommendations are easily
identifiable. This guideline meets the first criteria; the recommendations are specific regarding
consideration for use. The recommendations are laid out in a table format according to the
category of intervention and the recommendations for use in practice in one the six categories in
the ONS classification schema. The second criterion does not apply to this guideline. The third
criteria of easily identifiable recommendations is met and as stated previously the
recommendations are straightforward and laid out in a table format.
Overall, this guideline met its objective. The guideline is the outcome of a systematic
review and synthesis of the literature on oral adherence. However, the limitation it possesses is
not all the literature could be included due to the vast amount of research on the topic and this
author performing the review and synthesis single handedly.
Summary of Findings
Following my initial search, I located 142 relevant abstracts. Research and reviews
reporting on measuring adherence, factors contributing to non-adherence, and interventions to
improve adherence were included in the relevant abstracts. After review of the abstracts and
articles, I selected 119 for this review. Ultimately, I excluded 41 of the 119 as they were on
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measuring adherence or factors contributing to non-adherence and these two topic areas were
saturated with the reviews already completed. It was deemed that there would be no new and/or
additional information that could be gleaned from continuing review in these two areas. Upon
further review, 27 articles did not meet the inclusion criteria. The final outcome was the 51
articles that I included in this review. Of the 51, 14 were cancer related and 37 were related to
chronic disease (see Figure 1). The most common chronic diseases included cardiovascular,
diabetes, and HIV.

Figure 1. Tally of articles included in review.
Measuring Adherence
My synthesis of the data on methods used to measure adherence showed that the
Medication Possession Ration (MPR) and the Morisky Medication Adherence Scale were the
two most common methods used to measure adherence. The MPR is defined by the number of
doses dispensed in relation to a dispensing period (Netelenbos, J., Geusens, P., Ypma, G., &
Bujis, S., 2011). This requires analyzing pharmacy prescription refill data. The literature varies
on an exact percentage to be considered adherent, which is another issue related to measuring
adherence, but most concur that an adherence rate of 80% or greater is considered adherent. The
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Morisky scale is an eight-item, self-report measure of medication taking behavior. The criticism
with this method of measurement is that patient’s tend to overestimate their adherence or
deliberately misreport adherence to appear cooperative.
Of the seven articles that I reviewed and synthesized, only one was specific to
chemotherapy and neither of these scales was used in that study. Both of these scales have
widespread use in the chronic disease setting and whether they could be applied to measure
adherence in oncology patients is yet to be studied. The MEMS, which records time and date
when a medication container is opened, is another measurement tool seen in the literature,
however it is expensive and unlikely to see widespread use outside of clinical trials. Until further
research is conducted, specifically on how best to measure adherence to oral chemotherapy, no
recommendation can be made.
Factors Affecting Adherence
For this review I examined 21 articles specific for factors influencing adherence to oral
therapy; of these five were specific to oncology patients. There is a significant amount of
research examining the reasons for patient’s non-adherence. My review revealed numerous
factors. They include: (a) younger age (<45 years), (b) employed, (c) patient’s beliefs re: disease
and/or treatment, (d) low self-efficacy, (e) cost, (f) drug regimen complexity, (g) dosing schedule
and/or drug burden, (h) lack of drug information, (i) lack of social support, and (j) lack of health
care professional support (see Appendix B, Table B1).
Considering that this review did not include all possible research, it is possible there are
more factors. However, I feel confident this is a fairly comprehensive list of the factors affecting
adherence and they are the themes that repeated themselves in the literature which is the reason
the decision was made not to include any further articles looking at factors influencing
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adherence. One factor that I clearly identified in the research that affected adherence, depression
and/or cognitive function, was an exclusion for this review and therefore was not included as a
factor, but is clearly identified as contributing to non-adherence. It is worth mentioning that the
existing research often delineates between non-adherence being intentional versus nonintentional. For example, a patient who chooses not to take their medication because it makes
him or her sick is displaying intentional non-adherence versus a patient who simply forgets,
which would be non-intentional non-adherence. This is an important factor to assess for because
the interventions to support a patient are different depending on whether the non-adherence is
intentional versus non-intentional. Non-adherence is often multi-factorial and assessing the
reasons for patient non-adherence is necessary to tailor the appropriate interventions to improve
it.
Interventions to Improve Adherence
Twenty-three articles were reviewed for interventions to improve adherence, of which
three were in oncology patients (see Appendix B, Table B2). This synthesis and review
categorized the interventions by category. Those intervention categories are as follows: (a)
education, (b) psycho-educational, (c) packaging, (d) self-monitoring, (e) reminders, (f) cost, (g)
tailored, (h) targeted, (i) social support, (j) health care professional support, and (k) technology.
Some data in the interventions categories was not clear-cut and what I found in one study to
improve adherence was often contradicted in another. The ONS’ PEP classification schemas are
decision rules for summative evaluation of a body of evidence (see Appendix C). This
classification schema was developed by Mitchell and Friese, ONS members, to assist in
evaluating a collective body of evidence about a health intervention for the purpose of informing
decisions on implementation (Mitchell & Friese, n.d.). ONS PEP (Putting evidence into practice)
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Weight of evidence classification schema decision rules for summative evaluation of a body of
evidence.
There are three major components considered in classifying the collective evidence into
one of six weight of evidence categories (Mitchell & Friese, n.d.). The first is quality of data
with more weight assigned to higher levels of evidence such as randomized clinical trials and
meta-analysis. The second is magnitude of the outcome (effect size or minimal clinically
important difference) and the third is concurrence among the evidence. The six weight of
evidence categories that will be used to make recommendations for practice are: (a)
recommended for practice in which interventions for effectiveness has been demonstrated by
strong evidence from rigorously-designed studies, meta-analysis, or systematic reviews, and for
which expectation of harm is small compared with the benefits, (b) likely to be effective, in
which interventions for the evidence is less well established than those listed under
recommended for practice, (c) benefits balanced with harm in which interventions for which
clinicians and patients should weigh up the beneficial and harmful effects according to individual
circumstances and priorities, (d) effectiveness not established, in which the interventions
currently have insufficient data or data of inadequate quality, (e) effectiveness unlikely, for
interventions which lack of effectiveness is less well established than those listed under not
recommended for practice, and (f) not recommended for practice, for interventions which
ineffectiveness or harmfulness has been demonstrated by clear evidence, or the cost or burden
necessary for the intervention exceeds anticipated benefit (Mitchell & Friese, n.d.).
Dr. Margaret Irwin and I reached the following recommendations for practice for
interventions to improve adherence by consensus of two applying the PEP criteria. The
categories were developed by identifying the themes in interventions to improve adherence and
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grouping the results for ease of applying the criteria. The first category was education, which
includes verbal or written instruction and effectiveness is not established. The second category
was psycho-educational, which is education combined with a behavioral intervention and this is
deemed likely to be effective. The third category was packaging, (pill boxes/blister packs) and
this recommendation is likely to be effective. The fourth category was patient self-monitoring (of
side effects) and this is likely to be effective. The fifth category was reminders (of any kind) and
this category is recommended for practice. The sixth category was cost reduction (reducing copay/assistance) and effectiveness not established. The seventh category was tailored
interventions (pamphlets, letters, feedback) and likely to be effective. The eighth category was
targeted interventions (phone reminder, computerized phone call, automated voice call,
computer-aided instruction) and effectiveness is not established. The ninth category was social
support and effectiveness is not established. The tenth category was health care professional
support and effectiveness is not established. The eleventh and final category was technology
driven interventions (interactive computer, automated voice response) and is likely to be
effective.
It is significant to note that the only category of interventions that are recommended for
practice (the highest recommendation) are reminders. This signifies that there is relatively strong
evidence to show this intervention type matters. This should signify to the nurse that reminders
have been shown by the evidence to improve adherence and she/he should consider
incorporating this intervention into their patient teaching when appropriate. The recommendation
of likely to be effective should also be considered as these interventions also matter, and does not
mean there is not data to support their efficacy, rather the data is not as strong as that under
recommended for practice. The types of interventions are many and varied and ultimately they
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need to be individualized to each patient, keeping the evidence in mind.
Discussion of Findings in the Context Of Literature and Frameworks
The framework that I used for this project was the JHNEBP model. In addition to
applying the ONS PEP criteria for recommendations for practice, each article that I reviewed had
the JHNEBP criteria applied to grade the strength and quality of the evidence. This project may
continue on to become part of the ongoing work by the ONS PEP project team on oral
adherence, so it was therefore more important for me to apply ONS’ classification schema
criteria so this work could be considered for inclusion in the final resource developed by the
team.
My review and synthesis on ways of measuring adherence demonstrated a lack of a
consistent measurement tool to measure adherence to oral therapy. There was virtually no data
on a valid measurement tool in the oncology setting. This was consistent with the literature that
reports there is no gold standard to measure adherence (Sabate & WHO, p. 18) and no single
measurement strategy has been deemed optimal (Sabate & WHO, p. 19).
The literature on factors contributing to non-adherence is rich. This included, although to
a much lesser extent, some specific to the oncology patient. My review and synthesis revealed
numerous factors contributing to non-adherence and that non-adherence is multi-factorial.
Additionally, the importance of assessing for patient risk factors prior to the initiation of therapy
became apparent to me as the approach to assisting patients to remain adherent is likely different
depending on their risk assessment. The literature suggests that the reasons oncology patients are
non-adherent are often similar to the reasons chronic disease patients are non-adherent. This is a
significant finding because it then becomes reasonable to extrapolate the data on interventions
that have been proven to improve adherence in chronic disease patients (this data is lacking

35
specific to oncology patients) to oncology patients. This conclusion is also reflected in the
literature on factors contributing to non-adherence. Spoelstra and Given (2011) posited that
clinicians needed to assess for risk factors that may influence adherence and play a key role in
improving adherence by conducting ongoing assessment and measurement.
There have been a variety of studies examining interventions to improve adherence.
Most are in the chronic disease patient although the research is currently increasing in this arena
specific to the oncology patient as evidenced by the recent study by Spoelstra et al., (2013)
examining an intervention to manage symptoms and adherence in patients on oral oncolytics.
Based on this review and synthesis, there is minimal strong evidence around any single
intervention to improve adherence. Many studies reviewed for this study had methodological
flaws and were tested in very small populations (N<50). Therefore generalizations cannot be
made. However, when synthesizing the interventions by category, there are clearly some
interventions that should be considered for use in practice.
These findings are consistent with a review by Doggrell (2010) on adherence to
medicines in the older-aged with chronic conditions that there are many unanswered questions
about the most effective interventions for improving adherence. This project provided evidence
for what was posited by Sabate & WHO (2003, p.11): that adherence problems are observed in
all situations where the self-administration of treatment is required, regardless of type of disease,
disease severity, and accessibility to health resources.
My synthesis served to identify several areas where more research is needed. First, what
is an acceptable and valid measure of adherence? Second, what is the acceptable adherence
threshold and if that number varies depending on the oral oncolytic? For example, for drugs that
have a short half-life, missing a single dose may have more of an effect on disease progression
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than missing a dose of a drug with a long half-life. Unlike the HIV literature, which has an
answer to the adherence rate needed to keep the disease in check, oncology has yet to examine
this issue. Third, what interventions improve adherence in the oncology patient? Although it may
be determined by research that what helps chronic disease patients improve adherence also helps
oncology patients and vice versa, until more research is conducted, only assumptions can be
made.
Implications
Practice
I have demonstrated that the research is lacking in the area of adherence specific to oral
oncolytics. A major reason for this is the fact that there were a limited number of oral oncolytics
on the market until recent years. A shift in research and development and subsequent approval of
many oral oncolytics to market has created a new problem in the oncology arena. According to
Foulon et al. (2011) the steady increase in the use of oral anticancer drugs has created a paradigm
shift, challenging traditional attitudes towards cancer care and requiring new concepts of
organization of oncology services.
There is widespread attention to the issue across all oncology disciplines and the need for
more research is apparent. As there is no definitive answer to the best way to measure adherence
even in the chronic disease setting, research will be needed specific to oncology as to the best
method for measuring adherence. Understanding the reasons why patients are non-adherent can
contribute to developing interventions to improve adherence and my project uncovered common
themes in the literature that provides a fairly comprehensive understanding of the reasons why
patients are non-adherent. The vast majority of the literature is in the chronic disease setting.
What is assumed but unconfirmed by research is if those same reasons can be generalized to the
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oncology patient. Most of the literature that has looked at factors contributing to non-adherence
in the oncology setting has been in the realm of estrogen receptor modulators and aromatase
inhibitors. Although some of the reasons may be applied to all oncology disease states, it cannot
be said for certainty. The standard of care for this population of breast cancer patients requires
them to continue therapy for five years. The duration of therapy is a factor for non-adherence and
this duration is not the case with other oncolytics that patients take until disease progression or
unacceptable toxicities. In regards to interventions to improve adherence, there is a vast array of
literature especially in cardiovascular, diabetes, and HIV. There is a significant need to increase
the research being done to evaluate what interventions improve adherence specific to the
oncology patient. By providing nurses with an evidence-based resource that they can employ in
their practice, it is hoped that raising awareness and subsequent practice improvement around
education and monitoring patients on oral chemotherapy will improve the quality of care
provided to patients.
Implications for Social Change in Practice
The implications for social change are several. The first implication will be improved
patient care if adherence rates can be improved and better health outcomes will likely follow.
The final published outcome by the ONS PEP project team on oral adherence will provide nurses
with an evidence-based resource that they can use to guide their practice and ultimately
contribute to improving adherence. The second implication my project and the ongoing work by
ONS will determine is what areas are lacking in the research in the hopes that the unanswered
questions around adherence in the oncology patient can be studied. As the evidence develops it
will assist health care professionals to know how best to assess and monitor adherence and those
interventions to teach patients to assist them to remain adherent. The third implication, it is well
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established that when patients are adherent, health care costs decrease. Considering all medicine
related hospital admissions in the United States, 33%-69% are due to poor medication adherence
with a resultant cost of approximately 100 billion a year to society (Osterberg & Blaschke,
2005). Improving adherence can recognize not only an improvement in health outcomes but also
a cost savings to society. Sabate & WHO (2003, p. 22) posit that investments in improving
adherence are fully repaid with savings in healthcare utilization and the improvements in health
outcomes fully justifies the investment.
Health policy is an important way to recognize social change. A significant bill, titled
Improving Cancer Treatment Education Act of 2012 HR 3790, has been re-introduced to
Congress. In this bill it states that people with cancer benefit from having an education session
with oncology nurses in advance of the initiation of treatment. Additionally in the bill it states
that the Oncology Nursing Society has received reports from its members that because Medicare
and other payers do no cover patient treatment education, patients and caregivers often do not
receive adequate instruction before the initiation of therapy. ONS recommends that all patients
being treated for cancer have a one-on-one educational session with a nurse in advance of
beginning treatment. The bill also has language that speaks to the dichotomy of education that
currently exists between infused chemotherapy and oral chemotherapy (Govtrack.us, 2012).
Although education is just one piece to improving adherence, it is an important step in the right
direction. It is my opinion that passage of this bill into law to provide reimbursement for patient
education for chemotherapy teaching by a registered nurse will have a significant positive impact
on patient care.
A second policy issue is ensuring patients have access to oral chemotherapy without
undue financial burden as compared to intravenous chemotherapy. State parity legislation for
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oral chemotherapy drug coverage requires that insurance coverage for oral chemotherapy shall
be provided on a basis no less favorable than coverage for injectable or intravenous
chemotherapy. As of April 2013, twenty-two states and the District of Columbia have enacted
oral chemotherapy access laws with another 11 pending legislation (International Myeloma
Foundation, 2013). It is imperative that every state in the union has an oral chemotherapy parity
law in place so that patients have access to the therapy they need and that is prescribed without
financial hardship.
Lastly, public and healthcare payers are increasingly looking at the quality of cancer
centers as determined by specialty designations and certifications. One way for cancer centers to
demonstrate their commitment to high quality patient care is by achieving Quality Oncology
Practice Initiative (QOPI) certification. The QOPI certification program is a three-year
certification for outpatient hematology-oncology practices. It evaluates an individual practice’s
performance in areas that affect patient care and safety (Quality Oncology Practice Initiative,
(QOPI), n.d.a). Specific to this project are the measures around oral chemotherapy, including
education provided prior to the start of therapy and monitoring of that therapy on subsequent
visits (QOPI, n.d.b). It demonstrates that payers are recognizing the importance of quality
measures and that education and monitoring of oral chemotherapy (to which is adherence is tied)
is now being recognized as a quality measure. As more payers make it policy that in order to be
on a plan’s preferred network and be eligible for payment, a practice will be required to
demonstrate their commitment to quality, one way of which is through QOPI certification.
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Project Strengths and Limitations
Strengths
My project had several strengths. First it is on a topic that is prominent and problematic
in the oncology setting. Due to the lack of any significant research on the topic, this project was
the foundation of ongoing work by the ONS to publish an evidence-based resource on oral
adherence. Second, it was a systematic review and synthesis of the literature and the final
outcome of a guideline on oral adherence that nurses can use in their practice to assist in
providing evidence-based care. Third, the recommendations for practice were devised from the
ONS PEP classification schema, which has a strong and respected history in performing
systematic reviews and developing evidence-based PEP resources for nurses.
Limitations
This project was not without limitations. The project did not include all of the literature
on oral adherence. The volume of literature on oral adherence in the chronic disease setting is
vast and all of it could not be evaluated in the given time frame for this project. In hindsight, a
better approach may have been to examine the literature just on interventions to improve
adherence. Although a great deal of insight was provided in examining the measurement scales
and factors contributing to non-adherence, it did not allow for fully examining any one entity in
its entirety. Additionally, the amount of literature related to interventions is vast and the project
may have been better served to look at specific categories of interventions in their totality. For
example, evaluating the literature on all interventions that are tailored, targeted or technology
based. Despite the limitations, this guideline provides nurses with guidance on oral adherence
that they have not had available until now.
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Analysis of Self
Scholar
When embarking on this project, just how encompassing a systematic review and
synthesis of the literature would be was unknown to me. In retrospect, the goal was likely too
lofty. This experience taught me the need as a scholar to have a clear vision of the end product
desired and the path of how to best achieve that goal. It is not unusual to meet unforeseen
obstacles and challenges and as a scholar I needed to be skilled at understanding and navigating
this. My project as a DNP student epitomized the American Association of Colleges of Nurses
Essential III for Essentials of Doctoral Education for Advanced Practice Nurses which speaks to
using analytical methods to critically appraise existing literature and implement the best evidence
for practice and applying the relevant findings to develop practice guidelines and improve
practice and the practice environment (American Association of Colleges of Nurses, 2013, p.
12).
Practitioner
As a practitioner, working on a topic area for almost a year increases knowledge
exponentially. Although it can take years to become a subject matter expert, confidence and
comfort with the subject have resulted from this project. With my increased knowledge, I am
eager to share it with my colleagues and ignite a passion about the topic so that they will want to
improve this clinical practice issue in their practices. Additionally, performing a systematic
review and synthesis of the literature increases expertise in critiquing the literature. Prior to this I
thought I was able to critically read research but quickly learned it is a skill that takes practice
and instruction. Going through the critique process with my preceptor provided the opportunity
to learn from her expertise in this area. Although there is always more to learn, I now feel
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confident in my ability to critique, synthesize and draw my own independent conclusions about
the literature.
Project Developer
As a project developer, there were several lessons learned. First is to take advantage of
resources and let them be of help and be humble enough to ask for help when it is needed.
Second is to have a realistic vision of what can be accomplished in a given time frame and what
resources will be required to accomplish the goal. Also there is the skill required to maintain a
time line and the flexibility to adjust when those unforeseen obstacles present themselves. Last is
the ability to persevere and motivate people around you to be excited and willing to work on a
project that isn’t necessarily their passion.
Meaning for Future Project Development
Adherence to oral oncolytics is a rising issue in the oncology setting and there is much
work that needs to be done to improve this practice issue. The work to be done by the ONS
project team will continue at least till the end of this year and likely into early next year. It is the
expectation that I will continue to participate on this team after completion of this program and
see their project to fruition. If in fact, a PEP resource is published by ONS, it may provide an
opportunity to be published as a participant on this team. This topic is important to me and I
would like to continue to increase my knowledge around it, be a part of developing solutions for
it, and be recognized by my peers as a leader in the area of oral adherence.
Summary and Conclusion
Adherence to oral therapy has been a long-standing issue and challenge in the chronic
disease setting. Despite significant research in this arena, little improvement has been seen in
improving adherence in diseases such as cardiovascular, diabetes, and HIV. With the increase in
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oral chemotherapy drugs and subsequent paradigm shift in cancer care treatment, adherence in
the oncology patient is now being recognized as a clinical practice problem. Until the last
decade, oncology patients were educated and monitored by oncology nurses in the infusion suite
and practices were organized around this model of care. Patients prescribed oral chemotherapy
often have no interaction with a nurse and the remedy would require a workflow redesign, which
is not a simple or favored solution. This project started with the clinical practice problem of the
lack of evidence to guide nurse’s practice on managing patient’s on oral oncolytics. The resultant
guideline is a first step in providing nurses with the evidence to solving this practice problem.
Most of the research around adherence has been in the chronic disease setting and the
best we can do is to apply that research to oncology until more research is conducted in the
oncology setting. The final outcome of this project is a guideline for nurses to use as they interact
with patients prescribed oral chemotherapy. The recommendations for practice should be
considered and nurses should use this evidence and subsequent recommendations to guide their
teaching and monitoring. It would seem futile to suggest interventions that have been shown not
to improve adherence by the research. Conversely, nurses should consider those
recommendations likely to be effective or recommended for practice and use this evidence to
guide their interactions and education.
Adherence is important in all disease states to achieve the best clinical outcomes for
patients, but possibly more so in oncology where a patient’s survival is dependent upon taking
their medications as prescribed. Patient care is and will always be an inter-disciplinary effort;
however nurses have always taken the lead in educating patients. Oncology nurses need to have
an active role in conducting research, translating that research, and implementing it in the clinical
setting to allow oncology patients to have the best possible outcome for their disease. This work
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is a beginning step to provide nurses with the current state of the evidence and a guideline
around oral adherence to employ in their interactions with patients on oral chemotherapy.

45
Section 5: Scholarly Product
Summary and Conclusions
This systematic review and synthesis of the literature revealed that there has been very
little research conducted on adherence specific to oral oncolytics. As mentioned previously this
is in large part due to the fact that there have been limited oral oncolytics on the market until the
last several years so this observation is not surprising. However, there is a large amount of data
on oral adherence in the chronic disease setting and until more research is conducted in the
oncology patient that data will need to be extrapolated to the oncology patient.
The factors contributing to non-adherence have been well studied and the contributing
factors to non-adherence are well elucidated in the literature. The majority of factors, such as age
younger than 45 years, patient beliefs re: their disease and treatment, side effects, and cost just to
name a few, are all contributing factors to non-adherence. The research demonstrated that some
patients will have multiple contributing factors to non-adherence and some patients will have
none. The factors identified were repeated in the majority of studies reviewed. Although it
cannot be said with certainty, since the majority of the research has been conducted in the
chronic disease setting, it is reasonable to assume that the factors contributing to non-adherence
in patients with chronic disease are likely the same factors contributing to non-adherence in the
oncology patient. Considering the increasing number of oral oncolytics now in use as part of
cancer treatment, more research around the factors contributing to non-adherence specific to the
oncology patient may shed new light specific to this patient type or confirm what has already
been established in the chronic disease setting.
This literature review also critically appraised research on interventions to improve
adherence. Again, there is a large volume of research done in this area in the chronic disease
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setting, especially in HIV. The majority of studies reviewed established a lack of consistency in
identifying any single intervention that is superior in improving adherence. Many of the studies
were conducted in small numbers or in populations that do not allow for generalizations. The
synthesis did support the use of reminders as the one category of intervention type that proved
useful and improved adherence. As in factors contributing to non-adherence, the research is
lacking specific to oncology patients and more research is needed specific to this patient
population
This literature review and synthesis served to identify several areas where additional
research is needed. Until that research is conducted, extrapolations from the chronic disease
setting is reasonable to use as the evidence to guide nurse’s interactions with their patients
receiving oral chemotherapy. The following is a guideline developed from the synthesis of this
literature review on oral adherence and can be used by nurses to identify risk factors for nonadherence and those interventions which have been shown to improve adherence based on the
evidence. A first step in improving adherence is assessing for those risk factors that may
influence adherence followed by individualized patient/caregiver teaching and this guideline is a
tool that assists nurses to begin this process.
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Guideline on Oral Adherence
Background: Oral oncolytics continue to come to market at an unprecedented pace. Unlike
intravenous chemotherapy, which is administered in the controlled environment of the
chemotherapy suite and monitored by nurses, oral chemotherapy is administered in the patient’s
home and shifts the burden of administration and monitoring to the patient. There is currently no
gold standard definition of adherence. There is little information on how best to assess for
adherence and the majority of research on interventions to improve adherence has been done in
the chronic disease setting. In order for nurses to have an active role in improving this clinical
challenge, they need to know the current evidence around adherence. This guideline will provide
that evidence and recommendations for practice based on the systematic review and synthesis of
evidence completed on oral adherence.
Objective: To provide an evidence-based resource tool that nurses can employ in their practice
to guide their patient interactions with adult patients who are on oral chemotherapy. It is intended
to provide guidance for nurses to assess factors that may contribute to non-adherence and
identify what interventions are effective to facilitate patient adherence.
Search Methods: The literature was searched using Medline, PubMed, CINAHL, PsychInfo
from 1997-2013. Additionally, reference lists of papers that were eligible for inclusion in the
systematic review were scanned for additional citations. The literature search of the electronic
databases combined the following terms: medication adherence and oncology and/or cancer
and/or neoplasm and/or oral and/or chronic disease.
Selection Criteria: The search included the following designs: systematic reviews, metaanalysis, randomized controlled trials, and non-randomized comparative cohort studies. Articles
were selected for inclusion in the evidence series if they reported data on factors contributing to
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non-adherence and interventions to improve adherence. Case reports, letters, and editorials were
not considered for inclusion. Additionally, articles that included pediatrics, depression, cognitive
disorders, pregnancy, substance abuse, or clinical trials were excluded.
Data Collection & Analysis: One author independently selected studies for inclusion and
reviewed them. The evidence for factors affecting adherence was synthesized and the common,
repeating factors were identified. Interventions to improve adherence were synthesized and
grouped by category and the Oncology Nursing Society’s Putting Evidence into Practice
classification schema was used to determine the weight of the evidence in order to develop
recommendations for practice (see Appendix C). The classification schema was applied by two
individuals by consensus. Fifty-one articles were included in this review.
Main Results: Factors contributing to non-adherence: Numerous factors have been identified in
the literature that contributes to non-adherence. They include: younger age, employed, drug
burden, dosing schedule, patient’s belief system especially re: disease and treatment, side effects,
lack of social and/or Health Care Provider support, lack of drug education, low self-efficacy, and
cost. It is important to assess each patient individually for risk factors that may affect their ability
to be adherent. Table B1 can be considered a quick reference card and can be used to serve as an
assessment of these factors and assist in identifying those patients who may be at risk for nonadherence.
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Table 1
Factors Contributing to Lack of Adherence
Age younger than
45 years

Side Effects

Frequent dosing
schedule & high oral
drug burden

Lack of social support

Employed

Low self-efficacy

Complex drug regimen

Lack of Health Care
Provider support

Patient beliefs re:
disease (presence,
seriousness) &
treatment (necessity of
it, efficacy)

Cost

Lack of drug
information

Interventions to improve adherence have been mostly studied in the chronic disease setting.
Although the data is very limited specific to oncology patients, it is assumed that the
interventions shown to improve adherence in the chronic disease setting are likely to improve
adherence in the oncology patient. The interventions have been grouped by category and the
recommendations for use have been based on synthesizing the weight of the evidence using the
following classification schema:
Recommended for practice
Interventions for which effectiveness has been demonstrated by strong evidence from rigorouslydesigned studies, meta-analysis, or systematic reviews, and for which expectation of harm is
small compared with the benefits.
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Likely to be effective
Interventions for which the evidence is less well established than for those listed under
recommended for practice.
Benefits balanced with Harms
Interventions for which clinicians and patients should weigh up the beneficial and harmful
effects according to individual circumstances and priorities.
Effectiveness not established
Interventions for which there are currently insufficient data or data of inadequate quality.
Effectiveness Unlikely
Interventions for which lack of effectiveness is less well established than for those listed under
not recommended for practice.
Not recommended for practice
Interventions for which ineffectiveness or harmfulness has been demonstrated by clear evidence,
or the cost or burden necessary for the intervention exceeds anticipated benefit.
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Table 2
Recommendations on Intervention Categories to Improve Adherence

Education

Effectiveness not established

Psycho-educational

Likely to be effective

Packaging

Likely to be effective

Self-monitoring

Likely to be effective

Reminders

Recommended for practice

Cost
Tailored information (pamphlets, letters,
feedback, personalized info)
Targeted information (phone reminder,
computerized phone call, auto voice call,
personalized reminder, computer aided
instruction)

Effectiveness not established

Social support

Effectiveness not established

Health Care Provider support
Technology (interactive computer, phone,
automated voice response)

Effectiveness not established

Likely to be effective
Effectiveness not established

Likely to be effective

Author’s conclusions: There is little data around adherence to oral therapies in the oncology
setting so some extrapolations are necessary from the plethora of literature on the topic in the
chronic disease setting. Patients on oral anti-tumor therapy should be assessed for risk factors
known to decrease adherence while recognizing that there are many factors that contribute to
non-adherence. Some patients will have multiple factors while some may have none. Based on
their risk factor, interventions to assist with improving adherence should be tailored to the
patient’s risk factor while recognizing very few interventions have strong data to fully support
their use. However, reminders have been shown to be effective and should be recommended if
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appropriate. The categories recommended as likely to be effective should be considered when
appropriate, as there is evidence (not as strong as recommended for practice) to support their
consideration with patients. With the increased use of oral oncolytics more research is needed to
determine how best to measure adherence in the oncology setting and what interventions
oncology patients find most helpful.
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Appendix A: Conceptual Model of Project
Problem Identification:
Lack of patient education and monitoring
of patients prescribed oral oncolytics and
its contribution to non-adherence.

Systematic review of the literature

Appraise the
literature

Synthesize
the literature

Guideline for practice
recommendations

Present to ONS
for consideration
of future work on
topic

Present to
ONS Chapter
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Appendix B: Supporting Evidence for Guidelines on Oral Adherence
Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Sample

Findings

Limitations

FACTOR

stable breast cancer, 2
years post diagnosis
age

Atkins et al.,
qualitative
2006

multi/
UK

131

mean age=59.4 years
F=100%

longitudinal
Ediger et al.,
population
2007
based

Gatti et al.,
2009

qualitative

multi/
Canada

multi/
US

326

275

55% of woman reported non-adherence to
mediation frequently or occasionally, with
younger woman (95% CI, P=0.015) and those
who disliked taking their medication (P=0.001)
being significantly less adherent

diagnosis of IBD within
High adherence was reported by 73% of men and
previous 7 years
63% of women, for men, predictors of low
adherence included diagnosis and employment
median age=41 years
status (full-time); for women, younger age was a
predictor of low adherence
M=40%, F=60%

interview so pts
may have said
more desirable
responses, didn't
actually determine
preferable route

self-report,
volunteered,
mostly
Caucasian

used Grady Health
System to pick up
prescriptions, had been a
patient for at least 6
Younger patients (<65 years) had 2.5 times greater self-reported,
months
odds (95% CI) of low med adherence than >65
mostly AA
years.
population
avg age=53.9 years
M=27%, F=73%
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Iihara et al.,
single/
cross-sectional
2004
Japan

154

Sample

Findings

Limitations

chronic primarily liver,
GI or nervous system
51/154 showed intentional non-adherence,
diseases who had been
intentional non-adherence was associated with 1)
prescribed oral meds for
patients beliefs with respect to taking med without
regular use
self-report, culture
anxiety )(P<0.001), 2) poor comprehension of
general aspects of med (P<0.001), and 3) being in
“approx 60 years”
the prime of life (40-59years) (P=0.011).
M=60%, F=40%

Sedjo et al., retrospective
2010
cohort

multi/
US

women continuously
enrolled for at least 2
years and had breast
23% were non-adherent over 1 year; AI noncancer diagnosis in their
adherence was associated with younger age
13,593 first year
(<45 years), out of pocket cost of >$30 per AI
script as compared with <$10.
mean age= 55.5 years

filled Rx assumes
taken

F=100%

Tarantino et
al., 2010

RCT

single/
Italy

84

inpatients without mental 1 month post discharge 41.4% of uninformed
diseases who felt well
patients reported nonadherence vs 20.5% of
enough to complete the informed patients (P=0.03);younger age was
questionnaire
associated with nonadherence (p=0.003);
adherent patients perceived nonadherent behavior
mean age=66.4 years
to be more dangerous (P=0.001) than adherent
behavior and associated it with an absence of
M=44.3%, F=45.7%
benefits (P=0.024).

small sample, no
attentional
control,
questionnaire made
up by
investigators
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Tiv et al.,
2012

qualitative

multi/
France

3637

Sample

multi/
UK

131

Limitations

in univariate analysis many factors were associated
with adherence, gender and time from diagnosis
did not (P=0.93 and 0.90), working professionals
claimed reimbursement more nonadherent than non working (30% vs 15%,
for oral hypoglycemic P<0.001) and took med late more often (51% vs
agents and/or insulin at 35%, P<0.001); socio-demographic factors
self-report, # of
least 3 times between
associated with poor vs good adherence: age <45
meds not known,
Aug 2006 & July 2007 years (odds ratio=5.2), non European
self selected to
geographical origin (OR=2.6), financial
participate,
median age=64 years
difficulties (OR=1.7), professionally active
very lengthy
(OR=1.5). Health care related factors: difficulties
survey
M-n=2138
taking med alone (OR=3.8), decision making by pt
only (OR=3.3), poor acceptability of medical
F-n=1499
recommendations (OR=2.7), lack of social support
(OR=2.5), need for information (OR=2.0), no
confidence in future (OR=1.6), need for medical
support (OR=1.6), f/u by specialist (OR=1.4).

stable breast cancer, 2
years post diagnosis
disliked Atkins et al.,
qualitative
2006
med

Findings

mean age=59.4 years
F=100%

interview so pts
55% of woman reported non-adherence to
may have said
mediation frequently or occasionally, with younger
more desirable
woman (95% CI, P=0.015) and those who
responses, didn't
disliked taking their medication (P=0.001)
actually determine
being significantly less adherent
preferable route
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

personality

Axelsson et
qualitative
al., 2011

homes/
Sweden

749

Sample

Findings

Limitations

individuals who reported
diagnosed chronic
Negative relationship between Neuroticism and
disease
medication non-adherence (P=0.0011), while both low response rate,
Agreeableness (P=0.001) and Conscientiousness random sample
median age=53.5 years
(0.0.36) were positively related to adherence
M=43%, F=57%

dosing Bae et al.,
schedule 2012

CVD with prescription
for antidiabetic,
antihyperlipi-demic
retrospective
antiplatelet, or cardiac
multi/
cohort database
1,077,474agent
US
analysis
avg age=59
M=51%, F=49%

drug Benner et al.,
burden 2009

Retrospective
multi/
database
US
analysis

5759

The adjusted mean mediation possession ratio
(MPR) _+ standard error value for QD agents was
patients may get
13.6% greater than BID agents (P<0.01). The
Rx filled at low
adjusted mean MPR value for QD agents was
cost generic
2.9%, 17.5%, and 29.4% greater than BID agents
pharmacy and not
in the antidiabetic, antihyperlipidemic, and
show pharmacy
anitplatelet therapeutic classes. For cardiac agents,
claim (pay cash)
the adjusted mean MPR value was similar between
QD and BID agents.

patient enrollees in
managed care
organizations who were
Patients with 0 ,1 and 2 prior meds, 41%, 35%,
new users of
30% were adherent; among patients with 8, 9, and
antihypertensive and
>10 medications, 20.1%, 25.5%, and 20.1% were
lipid lowering therapy
adherent; as number of meds goes up, adherence
goes down
50%>65 years
M=52.3%, F=47.7%

assume Rx filled
means taken,
may have rec'd
samples or pd cash
would contribute to
underadherence
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Efficace et
al., 2012

qualitative

multi/
Italy

413

Sample

diagnosed in early
chronic phase of CML
and been in treatment
with imatinib for at least
3 years
median age=56.8 years

Findings

Limitations

53% of patients reported optimal adherence
behavior, multivariate model showed
concomitant drug burden (pts already on other adapted version of
meds may more easily add another) (P=0.006) MMAS,
greater level of social support (P<0.001) and
self-report
satisfaction with information received (P<0.001)
associated with optimal adherence.

M=59.56%, F=40.44%

beliefs

Bhattacharya
qualitative
et al., 2012

single/
UK

43

Non-adherence was reported by 23.3% of the 43
participants. Capecitabine was perceived necessary
dx with breast or
by 97.6%, but almost one-third of participants had
colorectal cancer and
strong concerns. Side effects were reported by
prescribed Capecitabine 80% of participants, with PPE and fatigue most
small sample,
troubling participants. Complete satisfaction with single site,
mean age=64.5 years
information received was reported by 65% of
self-report
participants, however, dissatisfaction about how to
M=44.2%, F=55.8%
tell if Capecitabine is working and the proposed
duration of therapy was expressed by 42.9% and
37.3% of participants, respectively.
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Sample
Findings
Limitations
Design
info
used Grady Health
System to pick up
prescriptions, had been a
patient for at least 6
Negative beliefs about meds had 2.1 greater odds self-reported,
Gatti et al.,
single/
months
qualitative
275
(95% CI) of low med adherence compared with mostly AA
2009
US
patients with less negative beliefs
population
avg age=53.9 years
M=27%, F=73%

Horne et al., cross-sectional multi/
1999
web survey
UK

324

chronic illness groups
prescribed 1 or more for
regular use in treatment
in their illness for at least
2 months prior to study Beliefs about medicines were related to reported
adherence; higher necessity scores correlated with
mean 45.4-63.6 years
higher reported adherence (r=0,21, P<0.01) and
higher concerns correlated with lower reported
M=37%-71%
adherence (r=0.33, P<0.001); gender, educational
F= 29%-63%
experience, or number of prescribed medicine did
Age and gender rates
not predict reported adherence.
vary depending on illness
group

self-report, can't be
sure about
direction of
causality b/w
beliefs
and behavior

67
Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Iihara et al.,
single/
cross-sectional
2004
Japan

154

Sample

chronic primarily liver,
GI or nervous system
diseases who had been
prescribed oral meds for
regular use
“approx 60 years”

Findings

Limitations

51/154 showed intentional non-adherence
,intentional non-adherence was associated with 1)
patients beliefs with respect to taking med
without anxiety )(P<0.001), 2) poor
self-report, culture
comprehension of general aspects of med
(P<0.001), and 3) being in the prime of life (4059years) (P=0.011).

M=60%, F=40%

Mann et al.,
qualitative
2009

single/
US

151

Type 2 diabetes for at
predictors of poor adherence were believing you
least 6 months who were
have diabetes only when your sugar is high, saying
prescribed diabetes
there was no need to take medicine when the
self-report, inner
medication
glucose was normal, worrying about side-effects city population
of diabetes medicines, lack of self-confidence in not generalizable
median age=57 years
controlling diabetes, and feeling medicines are
hard to take.
M=32%, F=57%
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

McHorney et
qualitative
al., 2010

multi/
US

Sample

one of six chronic
diseases: asthma,
diabetes,
hyperlipidaemia,
hyptertension,
19,023 osteoporosis, or other
cardiovascular disease
median age=59 years
gender not specified

Saratsioutou prospective
multi/
et al., 2010 observational Greece

99

Findings

Limitations

not generalizable
based on study
same four reasons were most commonly reported population to US
for both medication non-fulfillment and
population,
medication non-persistence: paying for the med a self-report, limited
financial hardship (56 & 43%), fear or experience responses to 10
of side effects (46 & 35%), generic concerns about for non-fulfillment
meds(32 & 23%), and lack of perceived need for and 12 for
non-persistence
the med(25 & 23%).
(could have been
more reasons)

19 patients reported unintended non-adherence,
most important factor relating to unintended
nonadherence was patient’s belief regarding
treatment effectiveness since only 16.7% of the
ca patients visiting the
patients believing that their treatment is effective
study centers pharmacy
reported nonadherence as opposed to 62.5% for
or MD’s to obtain their
those that did not believe the treatment is effective
oral med
small sample, self(P=0.03). Intentional nonadherence was reported
report
by 14 patients. The most important factor
median age=61 years
correlating to intentional nonadherence was time
since disease diagnosis, as nonadherence was
M=37%, F=62%
reported by 33.3% of patients having the disease
less than 6 months compared to 16.7% for those
between 6-24 months and 8.3% for those between
2-5 years (p=0.01).
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Tarantino et prospective
al., 2010
randomized

Unson et al.,
focus group
2003

single/
Italy

single/
US

84

Sample

inpatients without mental 1 month post discharge 41.4% of uninformed
diseases who felt well
patients reported nonadherence vs 20.5% of
enough to complete the informed patients (P=0.03);younger age was
questionnaire
associated with nonadherence (p=0.003);
adherent patients perceived nonadherent
mean age=66.4 years
behavior to be more dangerous (P=0.001) than
adherent behavior and associated it with an
M=44.3%, F=45.7%
absence of benefits (P=0.024).

age 60 or older not on
treatment for
osteoporosis
95
avg age=74.8 years
F=100%

side effects

Bhattacharya
qualitative
et al., 2012

single/
UK

43

Findings

Limitations

small sample, no
attentional
control,
questionnaire made
up by
investigators

small sample, ? If
there was fair
balance of drugs
presented, not
Adherence was associated with recognition of the
enough
serious consequences of nonadherence, realization
sociodemographic
of the beneficial efforts, and the belief that
data,
medicines are not harmful.
interviewers
background
dissimilar
to participants

dx with breast or
colorectal cancer and
prescribed Capecitabine Side effects were reported by 80% of participants, small sample,
with PPE and fatigue most troubling participants single site,
mean age=64.5 years
(did not tie to adherence measure).
self-report
M=44.2%, F=55.8%
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

McHorney et
qualitative
al., 2010

multi/
US

Sample

one of six chronic
diseases: asthma,
diabetes,
hyperlipidaemia,
hyptertension,
19,023 osteoporosis, or other
cardiovascular disease
median age=59 years
gender not specified

multi/
Hauber et al., cross-sectional
US &
2009
web survey
UK

407

Findings

Limitations

not generalizable
based on study
same four reasons were most commonly reported population to US
for both medication non-fulfillment and
population,
medication non-persistence: paying for the med a self-report, limited
financial hardship (56 & 43%), fear or experience responses to 10
of side effects (46 & 35%), generic concerns
for non-fulfillment
about meds(32 & 23%), and lack of perceived
and 12 for
need for the med(25 & 23%).
non-persistence
(could have been
more reasons)

type 2 diabetes currently
using GLM and not using
With no wt gain or CV risk, adherence was 73.5%, evaluating
insulin or Exenatide
wt gain of 9 kg decreases adherence by 30%, a 1 hypothetical
% point increase in heart attack risk results in
choices,
mean age=57 years
16.5% decrease in adherence.
poss selection bias
M=62%, F=38%

cost

retrospective
Briesacher et
database
al., 2009
review

starting generic drug
therapy
multi/
US

327,629

mean age=56 years
M=46.8%, F= 53.2%

Generic prescribing was associated with modestly overlap of chronic
improved adherence in 2 of 5 study conditions.
conditions,
Co-payments of $0 were associated with improved assume filled
adherence across all conditions.
means taken
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

McHorney et
qualitative
al., 2010

Sedjo et al., retrospective
2010
cohort

multi/
US

multi/
US

Sample

Findings

Limitations

not generalizable
one of six chronic
based on study
diseases: asthma,
same four reasons were most commonly reported population to US
diabetes, hyperlipidemia,
for both medication non-fulfillment and
population,
hyptertension,
medication non-persistence: paying for the med a self-report, limited
osteoporosis, or other
19,023
financial hardship (56 & 43%), fear or
responses to 10
cardiovascular disease
experience of side effects (46 & 35%), generic
for non-fulfillment
concerns about meds(32 & 23%), and lack of
and 12 for
median age=59 years
perceived need for the med(25 & 23%).
non-persistence
(could have been
gender not specified
more reasons)
women continuously
enrolled for at least 2
years and had breast
23% were non-adherent over 1 year; AI noncancer diagnosis in their
adherence was associated with younger age (<45 filled Rx assumes
13,593 first year
years), out of pocket cost of >$30 per AI script taken
as compared with <$10.
mean age=55.5 years
F=100%

longitudinal
Ediger et al.,
population
obstacles
2007
based

diagnosis of IBD within
previous 7 years
multi/
Canada

326

median age=41 years
M=40%, F=60%

self-report,
strongest predictor of adherence was the measure
volunteered,
of obstacles to adherence, the more obstacles, the
mostly
more likely to have low adherence.
Caucasian
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Sample

HIV positive, currently
prescribed ARV meds
Norton et al.,
qualitative
2010

multi/
US

327

Median age=45 years
Unintentional non-adh
group M=58.6%,
F=41.4%

Tiv et al.,
2012

qualitative

multi/
France

3637

Findings

Limitations

8.9% (29) reported taking a break without talking
self-report, pts may
to their HCP and classified as intentional nonadherent, 298 were unintentional non-adherent.
not have
Few differences were observed between
appropriately
answered single
intentional vs unintentional non-adherers on
demographic variables, adherence-related
question that
information, or motivation. Numerous differencesclassified them as
observed between groups on adherence-related intentional or
unintentional
behavioral skills (14 questions around how
hard or easy is it for you to…).

in univariate anaylsis many factors were associated
with adherence, gender and time from diagnosis
did not (P=0.93 and 0.90), working professionals
claimed reimbursement more nonadherent than non working (30% vs
for oral hypoglycemic 15%, P<0.001) and took med late more often
agents and/or insulin at (51% vs 35%, P<0.001); socio-demographic
least 3 times between
factors associated with poor vs good adherence: self-report, # of
Aug 2006 & July 2007 age <45 years (odds ratio=5.2), non European
meds not known,
geographical origin (OR=2.6), financial
self selected to
median age=64 years
difficulties (OR=1.7), professionally active
participate, very
(OR=1.5). Health care related factors: difficulties lengthy survey
M-n=2138
taking med alone (OR=3.8), decision making by pt
only (OR=3.3), poor acceptability of medical
recommendations (OR=2.7), lack of social support
F-n=1499
(OR=2.5), need for information (OR=2.0), no
confidence in future (OR=1.6), need for medical
support (OR=1.6), f/u by specialist (OR=1.4).
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

drug info/ Efficace et
education al., 2012)

qualitative

multi/
Italy

413

Sample

Findings

Limitations

diagnosed in early
chronic phase of CML
53% of patients reported optimal adherence
and been in treatment
behavior, multivariate model showed drug burden
with Imatinib for at least
adapted version of
((P=0.006) greater level of social support
3 years
MMAS,
(P<0.001) and satisfaction with information
self-report
received (P<0.001) associated with optimal
median age=56.8 years
adherence.
M=59.56%, F=40.44%

Iihara et al.,
single/
cross-sectional
2004
Japan

154

chronic primarily liver,
GI or nervous system
51/154 showed intentional non-adherence,
diseases who had been
intentional non-adherence was associated with 1)
prescribed oral meds for
patients beliefs with respect to taking med without
regular use
self-report, culture
anxiety )(P<0.001), 2) poor comprehension of
general aspects of med (P<0.001), and 3) being
“approx 60 years”
in the prime of life (40-59years) (P=0.011)
M=60%, F=40%

taking Capecitabine
Regnier et al.,
qualitative
2011

multi/
France

45

mean age=65.4 years
M=12%, F=88%

Patients said MD’s gave little information about
small sample,
treatment, doctors gave different amounts of
attentional control,
information and most important difference was
selection bias
about major side effects and how to manage.
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Design
info

Social/
Efficace et
HCP
al., 2012)
support

qualitative

multi/
Italy

413

Sample

Findings

Limitations

diagnosed in early
chronic phase of CML
53% of patients reported optimal adherence
and been in treatment
behavior, multivariate model showed drug burden
with Imatinib for at least
adapted version of
((P=0.006) greater level of social support
3 years
MMAS,
(P<0.001) and satisfaction with information
self-report
received (P<0.001) associated with optimal
median age=56.8 years
adherence.
M=59.56%, F=40.44%

Tiv et al.,
2012

qualitative

multi/
France

3637

in univariate analysis many factors were associated
with adherence, gender and time from diagnosis
did not (P=0.93 and 0.90), working professionals
claimed reimbursement more nonadherent than non working (30% vs 15%,
for oral hypoglycemic P<0.001) and took med late more often (51% vs
agents and/or insulin at 35%, P<0.001); socio-demographic factors
self-report, # of
least 3 times between
associated with poor vs good adherence: age <45
meds not known,
Aug 2006 & July 2007 years (odds ratio=5.2), non European geographical
self selected to
origin (OR=2.6), financial difficulties (OR=1.7),
participate,
median age=64 years
professionally active (OR=1.5). Health care related
very lengthy
factors: difficulties taking med alone (OR=3.8),
survey
M-n=2138
decision making by pt only (OR=3.3), poor
acceptability of medical recommendations
F-n=1499
(OR=2.7), lack of social support (OR=2.5), need
for information (OR=2.0), no confidence in future
(OR=1.6), need for medical support (OR=1.6),
f/u by specialist (OR=1.4).
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Table B1
Evidence Table for Factors Contributing to Lack of Adherence
Study
Site
Author
N
Sample
Findings
Limitations
Design
info
Gatti et al., qualitative
single/
275 used Grady Health
Patients with lower self-efficacy had 4.3 times
self-reported,
selfUS
System to pick up
greater odds (95% CI) of low med adherence
mostly
efficacy 2009
prescriptions, had been a compared with patients with higher self-efficacy. AA population
patient for at least 6
months
avg age=53.9 years
M=27%, F=73%
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Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info
Intervention: Education. Recommendation: Effectiveness not established

KonkleParker
randomized pilot
et al., 2008

Conn et al., Meta
2009
analysis

single/
US

multi/
not
stated

56

Findings

Limitations

At V-1 (1 mo after enrollment) adherence by
electronic measurement was 74.8%, 84.9% by
3 day recall and 90.3% by 3-4 wk VAS. At Vstarting ART for 1st time
small sample,
2 (3 mo later) and V-3 (3 months after V-2)
or restarting after at least 6
transient, lowself-reported adherence was consistently
months off med
income
100%; the electronic measurement showed
population, very
adherence rates ranging from 75-100% (V-2)
age=not stated
high attrition
and 60-86% at V-3. Significant correlation at
rate, 89% AA
V-1 between MEMS and other methods of
M=63%, F=37%
population
measurement with r=0.611 with 3 day recall
(p=0.046) and r-0.793 with VAS measurement
(p=0.004

Neither med nor disease education had any
meds to treat chronic
impact on effect size however, interventions
conditions in>60 years old with succinct written instructions achieved
Small number of
better effects on MA (SMD=0.61) than studies retrieved articles,
16-6,813 median age=67 years
without succinct written instructions
RCT only, high
(SMD=0.29). The difference between
heterogeneity, no
in studies reporting
providing any written directions (SMD=0.45 CI listed
gender, F>50% of sample and no written directions (SMD=0.28) was not
significant.
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Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Findings

multiple chronic
conditions
Williams et
multi/
systematic review
al., 2008
global

20-472

age=mostly >70 years

3/8 used education (pharm f/u) (1+, 2-)

gender not specified

Peterson et Meta
al., 2003
analysis

multi/
not
stated

Pt/consumer that had
intervention directed at
them; effect of tools and
methods designed to
enhance medication
36-12,424 adherence that have been
evaluated in RCT

Educational interventions: 7/22 was oral
teaching by MDs, in 5 cohorts pharmacist did
and nurses in 4; other interventions were
written or telephone education, mailed
material, emailed material, AV education-no
difference among intervention types r/t ES
Articles reviewed did not (p=0.441).
consistently report subject
characteristics

Limitations
No qualitative
studies, small
number
of studies,
studies done in
mostly
over 70 years of
age

Lack of
consistent data
and
well-controlled
trials, lack of
consistent
definition of
adherence

Intervention: Psycho-educational. Recommendation: likely to be effective
men and women living
with HIV undergoing ART
Kamau et
al., 2011

prospective
descriptive

multi/
Kenya

354

age-42% 31-40 years
M=28.6%, F=71.4%

positive relationship between coping selfefficacy and adherence to ART (p<0.05)

self-report,
convenience
sample
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Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Peterson et Meta
al., 2003
analysis

multi/
not
stated

Pt/consumer that had
intervention directed at
them; effect of tools and
methods designed to
enhance medication
36-12,424 adherence that have been
evaluated in RCT
Articles reviewed did not
consistently report subject
characteristics

combined
Peterson et Meta
(educ w/
al., 2003
analysis
behavioral)

multi/
not
stated

Pt/consumer that had
intervention directed at
them; effect of tools and
methods designed to
enhance medication
36-12,424 adherence that have been
evaluated in RCT

Findings

Behavioral interventions: 20/41 interventions
had dosage-schedule changes as primary
behavioral intervention, 11 had packaging
changes, 4 had telephone reminders, 6 had
other-no difference among groups r/t ES
(p=0.91)

Limitations

Lack of
consistent data
and
well-controlled
trials, lack of
consistent
definition of
adherence

Lack of
consistent data
Combined interventions: (oral education in
and
combo with behavioral) ES was 0.08 (95%
well-controlled
CI), mail reminders had largest impact (ES
trials, lack of
0.38), skill building (0.17), packaging changes
consistent
(0.14), dose schedule changes (0.12)
definition of
Articles reviewed did not
adherence
consistently report subject
characteristics

Intervention: Packaging. Recommendation: likely to be effective
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Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

randomized
Macintosh
prospective
et al., 2006
crossover

Conn et al., Meta
2009
analysis

single/
Canada

multi/
not
stated

18

Findings

solid tumors and were
planned to receive at least Adherence rates were similar with the two,
2 consecutive cycles of
81% with daily pill boxes and 86% with
Capecitabine
conventional pill bottles however more
patients were satisfied with daily pill boxes
median age=64 years
and thought daily box was more helpful in
reminding them to take their medications.
M-n=3, F-n=15

Limitations
small sample,
had to track with
diary
card which may
have served as
reminder and
increased
adherence

Packaging: MA interventions that included
med packaging changes (pillboxes, pill
cassettes, blister packs, special containers that
meds to treat chronic
indicate time of dose) were associated with
conditions in>60 years old
Small number of
larges ES (SMD=0.67) than interventions that
retrieved articles,
did not include packaging changes
16-6,813 median age=67 years
RCT only, high
(SMD=0.30).s were satisfied with daily pill
heterogeneity, no
boxes (61% vs 11%, P=0.027), preferred daily
in studies reporting
CI listed
pill boxes (61% vs 17%, P=0.061) and thought
gender, F>50% of sample
daily pill boxes were more helpful in
reminding them to take meds (50% vs 11%,
P=0.070)
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Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Findings

multiple chronic
conditions
Williams et
multi/
systematic review
al., 2008
global

20-472

age=mostly >70 years
gender not specified

1 study- IG-95.5% med adh, CG-69%,
P<0.001

Limitations
No qualitative
studies, small
number
of studies,
studies done in
mostly
over 70 years of
age

Intervention: Self-monitoring. Recommendation: likely to be effective
meds to treat chronic
conditions in>60 years old
Conn et al., Meta
2009
analysis

multi/
not
stated

16-6,813 median age=67 years
in studies reporting
gender, F>50% of sample

Small number of
Interventions that directed participants to selfretrieved articles,
monitor symptoms r/t meds were more
RCT only, high
effective (SMD=1.18) than interventions that
heterogeneity, no
did not include this component (SMD=0.30).
CI listed

Intervention: Reminders. Recommendation: recommended for practice
meds to treat chronic
conditions in>60 years old
(tech)

Conn et al., Meta
2009
analysis

multi/
not
stated

16-6,813 median age=67 years
in studies reporting
gender, F>50% of sample

Small number of
Interventions that included a stimulus to take
retrieved articles,
med (electronic device that makes sound) were
RCT only, high
more effective (SMD=1.06) than interventions
heterogeneity,
without cues (SMD=0.30).
no CI listed
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Revere et
al., 2001

(nontech)

Revere et
al., 2001

multi/
systematic review not
stated

multi/
systematic review not
stated

ambulatory patients
11-12,391

pt characteristics not
identified

ambulatory patients
11-12,391

pt characteristics not
identified

Findings
The interventions were categorized as mobile
communications (3 studies, all positive),
computer systems (9 studies, all positive),
automated telephone communications (10
studies, 9 positive, 1 negative)

Limitations
No cutting edge
technology
studied,
mostly health
behaviors vs
meds

No cutting edge
technology
print communications-24 studies, 20 positive, studied,
4 negative
mostly health
behaviors vs
meds

Intervention: Cost. Recommendation: effectiveness not established
enrollees taking 1 of 8
total not classes of drugs
Retrospective,
specified
pre-post quasibut ind
mean age
Farley et al., experimental study multi/
drug
participants=51.6, non
2012
design with a
US
classes had part=52.2 years
nonequivalent
many
control group
thousands M=36-57%, F=43-64%varied by drug class
Intervention: Tailored. Recommendation: likely to be effective

Value Based Insurance Design (VBID) was
associated with improved med adherence
ranging from 1.4% to 3.2% at 1 year, which assumption that
increased to 2.1% to 5.2% 2 years following rx filled means
VBID adoption. Adherence changes were most taken
notable among patients who were nonadherent before VBID implementation.
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

tailored

Conn et al., Meta
2009
analysis

Revere et
al., 2001

multi/
not
stated

multi/
Systematic review not
stated

Findings

Interventions that were individually tailored to
specific participant characteristics were less
meds to treat chronic
effective (SMD=0.06) than interventions that
conditions in>60 years old
were more standardized (SMD=0.37).Neither
minutes of intervention nor number of
16-6,813 median age=67 years
intervention sessions affected mean ES. Mean
predicted ES was highest for interventions
in studies reporting
delivered for 4 weeks (ES approx 0.7) but
gender, F>50% of sample
markedly reduced when interventions were
either of brief duration or very prolonged
ambulatory patients
11-12,391

pt characteristics not
identified

20-472 age=mostly >70 years
gender not specified

Intervention: Targeted. Recommendation: effectiveness not established

Small number of
retrieved articles,
RCT only, high
heterogeneity, no
CI listed

No cutting edge
Of the 23 tailored intervention studies, 22
technology
reported improved outcomes, 15 of these were studied,
statistically significant.
mostly health
behaviors vs
meds

multiple chronic
conditions
Williams et
multi/
Systematic review
al., 2008
global

Limitations

4/8 studies used tailored intervention (not
specified other than tailored) (1+, 3-),

No qualitative
studies, small
number
of studies,
studies done in
mostly
over 70 years of
age, pharm not
blinded in one of
these studies
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Revere et
al., 2001

multi/
Systematic review not
stated

ambulatory pts
11-12,391

pt characteristics not
identified

Findings

14 used targeted interventions, 11 of targeted
intervention studies reported improved
outcomes, 6 of these were statistically
significant

Limitations
No cutting edge
technology
studied,
mostly health
behaviors vs
meds

Intervention: Social Support (SS). Recommendation: effectiveness not established

GomesVillas et al., Descriptive
2012

single
site/
Brazil

162

type 2 diabetes under
outpatient follow-up with
insulin, oral anti-diabetic Direct but weak correlations were observed
limited time
and/or associated meds
between SS and non-med treatment adherence
period of study,
(r=0.21, p=0.01) as well as between SS and
self-report
avg age=59.4 years
med treatment adherence (r=0.18, p=0.02)
M=42%, F=58%

currently receiving ART
Kunustor et
RCT
al., 2011

single/
Uganda

174

mean age=39.1 years
M=32%, F=68%

Intervention: HCP Support. Recommendation: effectiveness not established

Mean adherence was 99.1% (95%CI:98.3%99.9%) for the TS arm and 96.3% (95%CT:
94.2%-98.3%) for the non-TS arm. The diff
was non signif (P>0.05)

showed no
difference but
author
says was
underpowered,
culture
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Farmer et
al., 2012

RCT

multi/
UK

211

Findings

type 2 diabetes of at least 3
months duration, currently
IG group=77.4% mean adherent days vs 69%
taking oral GLM and with
in CG;mean difference between groups in
HBA >7.5%
percentage of days that the correct number of
doses of med was taken as prescribed was
median age=63.2 years
8.4% (95% CI 0.2%-16.7%, p=0.0444);

Limitations

risk of biasattentional
control & no
blinding, selfreport

M=65.4%, F=34.6%
receiving home care
services for HIV/AIDS
Holzemer et
descriptive
al., 2000

single/
US

10

avg age=42.6 years
M-n=7, F-n=3

taking 4 chronic
medications
Lee et al.,
2006

RCT

single/
US

174

mean age=78 years
M=77.1 %, F=12.9%

Patients have knowledge and skill deficits
related to adherence (frequency=50%,
dose=50%, side effects=10%) and
management of s/e (thirst=60%, sweats=50%,
gas=30%, lightheadedness=30%, dry
mouth=20%, aches=20%)

small sample, no
control or
random
assignment, selfreport

After 6 months of the intervention, medication
adherence increased to 96.9% (p<0.001) and
was associated with significant improvements
in systolic BP (reduced from 133.2 to 129.9
mm Hg; p=0.02) and LCL-C (decreased from
91.7 to 86.8 mg/dl; p=0.001); six months after
randomization, the persistence of med
adherence decreased to 69.1% in usual care
arm, where it was sustained at 95.5% in
pharmacy care (p<0.001).

no random
assignment,
elderly, at
military hosp so
cost not issue

85
Table B2
Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Sherman et Retrospective non- multi/
al., 2009
case controlled
US

patients with at least 1
prescription for 1 or more
drugs within the 20
therapeutic classes
17,610 identified
mean age=60.39 years
M=55.72%, F=44.28%

prospective
Sommers et
observational
al, 2012
feasibility

single/
US

24

Findings

Limitations

Across the 20 therapeutic classes the
workplace treated patients had overall
adherence rates 9.72% higher than those of
community treated patients. The pattern was
repeated with an overall adherence rate that
pharmacy on site
was 9.52% higher for workplace treated
patients when prescriptions were limited to
medication new starts. Workplace treated
group was 26.7% more likely to have an 80%
or higher adherence rate (p<0.0001).

23/24 participants were able to verbalize
gastrointestinal cancer
knowledge of drug name, purpose, admin
short duration of
prescribed at least one oral schedule and what to do in case of
study,
chemotherapy agent
missed/skipped doses. All 24 reported using a
Hawthorne
method of tracking administration, including
effect, sm
mean age=53 years
themed diary, an alarm and reminders. 21/24
sample, no
were able to identify 1-3 side effects of their
attentional
M-n=23, F-n=7 (gender med but could not always identify the most
control, no
provided for initial n of
common side effect. MMAS-8 scores ranged
blinding
30)
from 5-8 (x=7.89, SD=0.55) with higher scores
indicating higher adherence.
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Williams et
RCT
al., 2012

single/
Australia

Findings

Limitations

patients with diabetes,
chronic kidney disease and
systolic hypertension
75

Mean adherence rate to meds was 22.2% in
small sample, not
control group and 24.3% in intervention group
mean age-68 years int arm,
generalizable
(p=0.162); no stat diff
66 years cont arm
M=56.4&, F=43.6%
5 or more drugs on at least
2 consecutive visits to
clinic

Wu et al.,
2006

RCT

Single/
Hong
Kong

442

Fewer patients who were non-compliant at
enrollment remained non-compliant at end of
Mean age=71.2 years in
study in intervention group than in control
int group, 70.5 in control
group (7% v 18%, p<0.001). More patients
group
who turned compliant at enrollment remained
compliant in the intervention group than in the
M=49% int group, 48%
control group (81% v 58%, p=0.038).
control group, F=51% in
int group, 52% in control
group

Intervention: Technology. Recommendation: likely to be effective

no blinding, no
attentional
control,
self-report, single
site, >10% w/d
but d/t deaths
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info
prescribed ART
(antiretroviral therapy)
Fisher et al.,
RCT
2011

multi/
US

328

mean age=47%
gender not stated

receiving ART
Kalichman,
RCT
et al., 2011

single/
US

40

mean age=51 years
M-n=26, F-n=14

Piette et al.,
RCT
2000

multi/
US

diabetes >6 months and
using hypoglycemic
medication
280
mean age=55 years
M=41%, F=59%

Findings
For ITT, an increasing proportion of
participants in the intervention arm reporting
perfect adherence on ACTG 3 day adherence
measure (p=0.12) and on the VAS 3-4 week
adherence measure (p=0.12) as time
progressed from baseline did not reach
statistical significance.

Limitations

high withdrawal,
requires
hardware
& software

adherence improved from 87% of pills taken at
baseline to 94% adherence 4 months after
small sample,
baseline (p<0.01). Effect sizes ranged from
convenience
moderate (d=0.45) to large (d=0.80). Gains in
sample
adherence were paralleled with increased selfefficacy (p<0.05) and use of behavioral
strategies for ART adherence (p<0.05).

Automated telephone assessment and self care
education calls with nurse follow up increased unblinded, selfadherence to medications (48% vs 69%,
report
p=0.003)
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Lawrence et
RCT
al., 2008

Reidel et
al., 2008

feasibility

multi/
US

multi/
Canada

Findings

Limitations

155

participating in disease
In 17 months of program experience, 199 late
management programs for med refills among a 155 patients and controls,
CVD or diabetes
in the intervention group, 123 late meds for 94
patients, in control group, 76 late meds in 61 no blinding, short
age range=18-65 years
patients. Intervention group had a significantly study period,
higher rate of med reinitiation (59.3) than the pts self-selected
M=51.1 years int group, control group (42.1) (P<0.05). Time to
to participate
42.6 in control group,
reinitiation was significantly shorter in the
F=47.9 years in int group, intervention group 59.5 days vs 107.4 days for
57.4 in control group
control group.

99

patients enrolled in
The majority found IVR system’s voice
electronic prescribing and
acceptable and did not have problems setting
medication management
up the time and location of reminder calls.
who were taking chronic
Many experienced technical problems when
disease related drugs in the
called for reminders, such as incorrect time of
3 months prior to start of
calls and voice recognition difficulties. Most
study
participants had already refilled their
prescriptions when they received the reminder
age=60->80 years,
calls, reporting they did not have difficulties
45.5%=70-79 years
remembering to refill prescriptions on their
own.
M=47.4%, F=52.6%

self-selected
group, study
terminated
early d/t
technical flaws
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Evidence Table for Recommendations on Intervention Categories to Improve Adherence
Site
Author
Study Design
N
Sample
info

Spoelstra et
RCT
al, 2013

multi/
US

91

Findings

Limitations

solid tumor cancer dx and Q1-comparisons on adherence rates: 42%
being on nonhormonal oral were nonadherent, for those who completed all
agents
8 AVR calls adherence rate increased 9%
small sample,
(p=0.11) in the AVR + nurse for sx and adh >10% w/d, selfmean age=59.6 years
strategies, AVR + nurse for adh only increased report
by 3% (p=0.54) and declined by 4% (p=0.36)
M=30%, F=70%
in the AVR plus SMT only.

Q2-comparisons on symptom severity:
Group 1 mean scored decreased 4.74, p=0.03,
group 2 mean score decreased 6.76, p=0.04
and group 3 had no significant decrease in
symptom severity, mean scored decreased
2.16, p=0.39.

Q3-comparison on adherence and symptom
severity-multivariate analysis showed no
signif differences between groups in symptom
severity at baseline and at end of study.
Symptom severity declined in all and there
were no signif differences between groups.
Type of intervention did not make a difference
in symptom severity.
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Appendix C: ONS Putting Evidence into Practice Weight of
Evidence Classification Schema1
S.A. Mitchell, MScN, CRNP, AOCN® and C.R. Friese, PhD, MS, RN,
AOCN®
On behalf of the ONS Oncology Nursing Interventions for Patient Outcomes Project
Team
Background
The classification schema outlined below was developed to assist in evaluating a
collective body of evidence about a health intervention for the purpose of informing
decisions on implementation. Based on the work of Ciliska, Cullum and Marks
(2001), Hadorn, Baker, Hodges and Hicks (1996), Rutledge, DePalma, &
Cunningham (2004), and Ropka and Spencer-Cisak (2001), the schema was intended
for application to bodies of existing research-based knowledge on health
interventions for patients with cancer. The schema itself does not seek to guide the
decision process in relation to an intervention for an individual patient. Such
decisions should be made within the interdisciplinary team, and based on individual
patient characteristics, values, and preferences, a consideration of potential harms as
well as benefits, and an assessment of the feasibility of implementing the intervention
within the specific care setting.
A schema developed for appraising evaluative research should not be used to remove
interventions from further consideration because of inadequate evidence about
intervention effectiveness. Criterion-based evaluation of evidence is valid only where
a significant body of high quality evidence is available. It is critical to avoid
interpreting insufficient evidence on the one hand, or poor-quality evidence on the
other, as meaning that an intervention is unimportant or ineffective. Insufficient
evidence or a lack of evidence simply means that evaluative research of an
intervention has not been done at the level necessary to make conclusions with
confidence that an intervention produces a specific outcome/patient benefit. The lack
of evidence on an intervention, or the availability only of poor-quality evidence, may
indicate a gap in knowledge and a need for additional research. The schema can
therefore also be used to highlight research gaps, and to identify the types of research
that could address those gaps.
Panels of advanced practice nurses, staff nurses, and doctorally-prepared nurse
researchers reviewed the literature base in the identified outcome areas. Professional
1

Note. From ONS PEP (Putting Evidence Into Practice) Weight of Evidence Classification Schema:
Decision Rules for Summative Evaluation of a Body of Evidence. Retrieved from
http://www.ons.org/research/media/ons/docs/research/outcomes/weight-of-evidence-table.pdf. Copyright
by Oncology Nursing Society. Reprinted with permission.
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ONS PUTTING EVIDENCE INTO PRACTICE
O
ONS PEP (Putting Evidence into Practice) WEIGHT OF EVIDENCE
CLASSIFICATION SCHEMA
Decision Rules for Summative Evaluation of a Body of Evidence
health services librarians assisted in the conduct of the literature searches. Based on
their analysis, the panels then formulated a judgment about the body of evidence
related to the intervention under consideration. Three major components were
considered by the panels in classifying the collective evidence into one of six Weight
of Evidence categories:
•
•
•

Quality of the data, with more weight assigned to levels of evidence higher in the
PRISM categorization (such as randomized trials, and meta-analyses)
Magnitude of the outcome (eg. effect size or minimal clinically important
difference)
Concurrence among the evidence (based on the premise that an investigator
has less confidence in findings in which the lines of evidence contradict one
another)

Recommended for Practice
Interventions for which effectiveness has been demonstrated by strong evidence from
rigorously-designed studies, meta-analyses, or systematic reviews, and for which
expectation of harms is small compared with the benefits.
•

Supportive evidence from at least two well-conducted randomized controlled
trials that were performed at more than one institutional site, and that included a
sample size of at least 100 participants

•

Evidence from a meta-analysis or systematic review of research studies that
incorporated quality ratings in the analysis, and included a total of 100 patients
or more in its estimate of effect size and confidence intervals

•

Recommendations from a panel of experts, that derive from an explicit literature
search strategy, and include thorough analysis, quality rating, and synthesis of
the evidence

Likely to Be Effective
Interventions for which the evidence is less well established than for those listed under
‘recommended for practice’’.
• Supportive evidence from a single well conducted randomized controlled trial
that included fewer than 100 patients or was conducted at one or more
institutions
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ONS PUTTING EVIDENCE INTO PRACTICE
O
ONS PEP (Putting Evidence into Practice) WEIGHT OF EVIDENCE
CLASSIFICATION SCHEMA
Decision Rules for Summative Evaluation of a Body of Evidence
• Evidence from a meta-analysis or systematic review that incorporated quality ratings
in the analysis and included fewer than 100 patients, or had no estimates of effect
size and confidence intervals
• Evidence from a synthetic review of randomized trials that incorporated
quality ratings in the analysis
• Guidelines developed largely by consensus/expert opinion rather than primarily
based on the evidence and published by a panel of experts, that are not supported
by synthesis and quality rating of the evidence
Benefits Balanced with Harms
Interventions for which clinicians and patients should weigh up the beneficial
and harmful effects according to individual circumstances and priorities.
• Supportive evidence from one or more randomized trials, meta-analyses or
systematic reviews, but where the intervention may be associated, in certain patient
populations, with adverse effects that produce or potentially produce mortality,
significant morbidity, functional disability, hospitalization or excess length of stay
Effectiveness Not Established
Interventions for which there are currently insufficient data or data of inadequate
quality.
• Supportive evidence from a well conducted case control study
• Supportive evidence from a poorly controlled or uncontrolled study
• Evidence from randomized clinical trials with one or more major or three or
minor methodological flaws that could invalidate the results

more

• Evidence from non-experimental studies with high potential for bias (such as case
series with comparison to historical controls)-Evidence from case series or case
reports
• Conflicting evidence, but where the preponderance of the evidence is in support of
the recommendation or meta-analysis showing a trend that did not reach statistical
significance
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Decision Rules for Summative Evaluation of a Body of Evidence
Effectiveness Unlikely
Interventions for which lack of effectiveness is less well established than for those
listed under ‘not recommended for practice’.
• Evidence from a single well conducted randomized trial with at least 100
participants or conducted at more than one site and which showed no benefit for the
intervention
• Evidence from a well conducted case control study, a poorly controlled or
uncontrolled study, a randomized trial with major methodologic flaws, or an
observational study (eg. case series with historical controls) that showed no benefit
and a prominent and unacceptable pattern of adverse events and serious toxicities
(CTCAE Grade III/IV)
Not Recommended for Practice
Interventions for which ineffectiveness or harmfulness has been demonstrated by
clear evidence, or the cost or burden necessary for the intervention exceeds
anticipated benefit
• Evidence from two or more well conducted randomized trials with at least 100
participants or conducted at more than one site and which showed no benefit for the
intervention, and excessive costs or burden expected
• Evidence from a single well conducted trial that showed a prominent and
unacceptable pattern of adverse events and serious toxicities (CTCAE Grade
III/IV)
• Evidence from a meta-analysis or systematic review of research studies that
incorporated quality ratings in the analysis, included a total of 100 patients or
more in its estimate of effect size and confidence intervals with demonstrated lack
of benefit or prominent and unacceptable toxicities
• Intervention discouraged from use by a panel of experts in the related subject, after
conducting a systematic examination, quality rating and synthesis of the available
evidence
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